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JAB1 NEGATIVELY REGULATES PTEN AND PROMOTES RESISTANCE TO TRASTUZUMAB IN
HER2-POSITIVE BREAST CANCER

Thuy Vu, B.S.
Advisory Professor: Francois X. Claret, Ph.D.

HER2-positive breast cancer, which is characterized by the over-expression of the
HER2 onco-protein, accounts for approximately 20% of all breast cancer cases.
Trastuzumab (Herceptin), the first targeted therapy approved for HER2-positive
disease, potently prevents the activation of signaling pathways downstream of HER2
and significantly improves patients’ outcomes. However, resistance to trastuzumab is
inevitable; such resistance can occur through reduced expression of PTEN protein.
Jab1 is over-expressed in 50% of primary cancers and 90% of metastatic tumors. Our
lab previously showed that depletion of Jab1 in combination with trastuzumab
treatment up-regulated PTEN in mouse xenografts refractory to trastuzumab. PTEN
was not detected in the control Jab1 knockdown. However, how Jab1 modulated
trastuzumab responses and affected PTEN function was incompletely understood. The
overall goal of my project was to identify the role of Jab1 in regulating PTEN and in
contributing to trastuzumab resistance in HER2-positive breast cancer. I demonstrated
that Jab1 mediated the post-translational regulation of PTEN by associating with PTEN
and facilitating its degradation. I also found that the C-terminal end of Jab1 was
required for Jab1 to induce degradation of PTEN. Furthermore, I showed that
proteasome inhibitors failed to prevent PTEN degradation induced by Jab1 overexpression in breast cancer cells. Instead, the combination of lysosomal protease
VI

inhibitors - E64D and pepstatin A - significantly impaired the ability of Jab1 to degrade
PTEN. Further, I showed that silencing Jab1 increased trastuzumab’s inhibitory effects
on cell proliferation. In contrast, the introduction of Jab1 into breast cancer cells
conferred resistance to trastuzumab. Taken together, my findings suggest that Jab1
negatively regulates PTEN and promotes trastuzumab resistance in HER2-positive
breast cancer.
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CHAPTER 1: INTRODUCTION

Summary list:

1. Breast cancer, a heterogeneous disease, is the most frequently diagnosed cancer
in women and the second leading cause of cancer-related death for women worldwide.
2. HER2+ breast cancer is characterized by the amplification or over-expression of
the HER2 oncogene/protein and accounts for about 15-20% of all breast cancers.
3. Trastuzumab (Herceptin) is the first targeted therapy approved for HER2+ breast
cancer.
4. Though trastuzumab significantly improves patients’ overall survival, resistance to
the drug is inevitable.
5. Partial or complete loss of PTEN, which promotes p-Src-Y416 and p-AKT-S473, is
one of the proposed key factors that leads to trastuzumab resistance.
6. Jab1, which is frequently amplified/over-expressed in breast cancer, potently
promotes cell proliferation by binding to and causing rapid degradation of p27.
7. The ubiquitin-proteasome system accounts for the degradation of about 80% of
intracellular proteins. In general, a protein is first attached to a K48-linked poly-ubiquitin
chain, and then is transported to the proteasome for degradation.
8. The lysosomal proteolytic pathway does not require its target proteins to be polyubiquitinated and functions in three distinct ways: macro-autophagy, chaperonemediated autophagy, and micro-autophagy. Proteins tagged with a K63-linked polyubiquitin chain have been found to be degraded by the lysosomal proteolytic pathway.

1

OVERVIEW OF BREAST CANCER

Breast cancer is the most frequently diagnosed cancer in women, which
accounts for 23% of the total cancer cases worldwide and 29% of all new cancer cases
in the United States (Figure 1) (1). Moreover, breast cancer is now the second leading
cause of cancer-related death in women in both developed and developing countries,
which accounts for 14% of the cancer deaths (1, 2).

2

Figure 1. Ten most popular cancer types based on estimated new cases in
women in United States in 2014.

Breast cancer is the most frequently diagnosed cancer in women.
Adapted with permission from CA Cancer J Clin, Siegel, Ma, Zou, and Jemal, copyright
2014 (1)
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1. Development of breast cancer

Breast cancer or breast carcinoma is a complex and heterogeneous disease,
comprising multiple tumor individual cells with distinctive histological patterns, different
biological and clinical behaviors (3-5). Simply defined, breast cancer is initiated by the
uncontrolled growth and proliferation of cells developing in an area of the breast (Figure
2) (5, 6). Specifically, most breast tumors arise at the junction between the terminal
duct and lobule named terminal ductal lobular units (4).
Terminal ductal lobular units are comprised of luminal epithelial (or epithelial)
and myoepithelial cells (5, 7). Mutations accumulated inside breast epithelial cells lead
to the uncontrolled growth and proliferation of the cells and subsequently lead to breast
tumor (Figure 2) (5, 6). As each mutation is accumulated, a non-invasive lesion can
increase the risk of developing malignant or invasive breast cancer. Once cancer cells
have invaded, the risk for developing metastasis significantly increases (Figure 2) (5).
The lymph nodes are the primary site for breast cancer metastasis (5).

4

Figure 2. A simplified schematic of breast cancer progression.

Breast cancer is initiated by the genetic or epigenetic changes in breast (luminal)
epithelial cells. Subsequent cell transformation and tumor progression are driven by the
accumulation of additional genetic changes. The metastasis is formed when the tumor
cells sustain proliferation and invade through the basement membrane, enter the
vasculature, and establish a new tumor in a new microenvironment.
Modified with permission from Nat Rev Cancer, Vargo-Gogola and Rosen, copyright
2007 (5)
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2. Classification of breast cancer

Traditionally, pathologists classified breast cancer into non-invasive and invasive
types, based primarily on overall morphology, structural growth pattern, histological
grade, and presence of lymph-node metastasis (4). Noninvasive breast carcinoma is
detected when cancer cells fill the ducts but haven't spread into surrounding tissue,
which is called ductal carcinoma in situ (DCIS). DCIS indicates a precursor to invasive
breast cancer (3, 5).
Invasive breast cancer occur when the cancer cells have penetrated the lining of
the ducts or lobules and are found in the surrounding tissues, such as fatty and
connective tissues (5). The two most common histological subgroup of invasive breast
cancer are infiltrating ductal and infiltrating lobular carcinomas (3). Compared with
infiltrating ductal carcinoma, invasive lobular carcinoma is more likely to occur in older
women, tends to be better differentiated, shows favorable outcomes, and metastasizes
later (8-10). The other rare types of invasive breast tumor account for less than 10% of
all cases include medullary, mucinous, tubular, papillary, metaplastic, and inflammatory
types (3, 7). Patients with ductal, lobular, and medullary carcinomas have about 10year survival rates, while mucinous and tubular carcinomas have relatively better
overall outcomes (3, 7).
In the modern clinical practice, the emergence of fluorescence in situ
hybridization (FISH) and advances in genomic profiling have provided new insights into
breast cancer taxonomy (11). The initial study was done by Perou, Sorlie, and their
colleagues who performed comprehensive analysis of genetics and molecular biology
on different sets of cancer cell lines and tissues from breast cancer patients (12, 13).
6

Follow-up studies from these groups and from the Cancer Genome Atlas Network
confirmed their findings that breast cancer can be defined into 4 major subtypes,
luminal A, luminal B, basal-like and HER2-positive (HER2+) breast cancer which
makes up about 80% of all breast cancer cases (table 1) (7, 11, 14, 15). The
classification was primarily based on the presence or absence of estrogen receptor
(ER), progesterone receptor (PR), and human epidermal growth factor receptor 2
(HER2) (11). Luminal A and B tumors are generally associated with more favorable
prognosis, compared to tumors lacking ER and PR expression such as HER2 and
basal-like breast cancers (Figure 3) (11). The understanding of these heterogeneities
has paved the way for the development of personalized targeted therapy in the
treatment of breast cancer (table 1) (11). For comprehensive overviews of breast
cancer, therapeutic implications, and updated reports on breast cancer incidence,
readers are recommended to peruse excellent reviews by Sims et al (2007), VargoGogola et al (2007), Weigelt et al (2009), and Bertos et al. (2011) (4, 5, 7, 11).
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Table 1. Portraits of human breast tumour subtypes based on molecular
pathology (11).
Abbreviations: minus signs indicate the negativity; plus signs indicate the positivity.
Luminal A

Luminal B

HER2-positive

Basal - like

Luminal

Basal luminal

Basal luminal

Basal

ER+

ER+

ER-

ER-

PR-/+

PR-

PR-

HER2-

HER2+

HER2+

HER2-

Histological

I (well

III (poorly

III (poorly

III (poorly

Grade

differentiated)

differentiated)

differentiated)

differentiated)

Incidence

40%

20%

18-20%

15-20%

Associated

More common

Higher risk at

with increasing

at young age

young age

Predominant

African

African

ethnicity

American

American

Cancer cell
phenotype
Molecular

characteristics PR-/+

age

Approved

Endocrine

Chemotherapy Chemotherapy

Heavy

therapy

therapy (anti-

and/or

and/or

chemotherapy

estrogen or

endocrine

HER2 targeted

aromatase

therapy

therapy (for ex.,

inhibitors)

trastuzumab)
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Figure 3. Prognostic outcome for each breast cancer subtype by molecular
profiling.

The HER2+ (ERBB2+) and basal subtypes demonstrate the worst prognoses, whereas
the luminal subtype A and B show the more favorable outcome.
Abbreviation: HER2+, HER2 positive.
Modified with permission from Nat Rev Cancer, Vargo-Gogola and Rosen, copyright
2007 (5)
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HER2-POSITIVE BREAST CANCER

In my studies, I focused on HER2+ breast cancer which is characterized by the
amplification or over-expression of HER2 onco-gene or –protein

1. Biology of HER2 and the family of the epidermal growth factor receptors

Human epidermal growth factor receptor-2 (HER2) is a 185 kDa transmembrane
receptor which is encoded by HER2 gene located on the long arm of chromosome 17
(17q12–21.32) (16, 17). HER2 protein was first found to be homologous to neu, a
rodent oncogenic growth factor receptor (18, 19). The neu oncogene was initially
discovered in a carcinogen-induced rat-brain tumor model and was a homolog of the verbB (avian erythroblastosis virus) viral oncogene (16, 20). Later, HER2 was found to
be amplified in human breast cancer cell lines and had tyrosine kinase activity similar to
the other epidermal growth factor receptor (EGFR). The post-genome characterization
of the human kinome completed the description of this HER family which comprise four
members: ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4) (Figure 4)
(16).
Their structures, in general, consist of 3 distinct domains, the extracellular
ligand-binding domain, the transmembrane domain and the cytoplasmic kinase domain.
The extracellular domain contains the ligand-binding cleft which mediates the
dimerization of each receptor while the cytoplasmic domain contains the ATP binding
pocket (Figure 4) (16). Once activated by a ligand, HER proteins undergo dimerization
then recruiting ATP to their binding pocket and undergo trans-phosphorylation in the
10

tyrosine residues. These phosphorylated residues trigger various molecular pathways
associated with tumor growth and progression (16). Of note, no known ligand has been
found for HER2, which implies that HER2 activation preferred heterodimerization with
the other members of the family (21). On the other hand, HER3 lacks ATP binding site
and is catalytically inactive, which indicates that signaling functions of HER3 are
mediated through the kinase activity of its heterodimeric partners (16, 22). Many
studies have demonstrated that HER3 is not only the preferred partner for the
activation of HER2 but HER2-HER3 dimer is also the most active signaling of the family
(23-25).
One of the major and most well-studied pathways downstream of HER2
activation is the phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (AKT) pathway
(See section “Molecular mechanisms of actions of trastuzumab”) (23, 25-27).
Preclinical and clinical studies showed the frequent activation of AKT in HER2 overexpressing human breast tumors, which promoted cell proliferation and survival (28,
29). For a comprehensive review on HER2 oncogen, its signaling and its tumorigenetic
effects, please refer to review by Moasser (2007) (27).
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Figure 4. Structures of the four members of the HER receptor family.

The HER receptor family is composed of four members, EGFR, HER2, HER3, and
HER4. Each receptor has 3 distinct domains, the extracellular, transmembrane and
cytoplasmic domains. The dimerization loop and the ligand-binding cleft on the
extracellular domain were marked by dashed circles and black arrows, respectively.
The ATP-binding pocket on the cytoplasmic domain was marked by white arrows.
There is no known ligand reported for HER2.
Abbreviations: AR, amphiregulin; BTC, betacellulin; EGF, epidermal growth factor;
EGFR, epidermal growth factor receptor; EPR, epiregulin; HBEGF, heparin-binding
EGF; NRG, neuregulins; TGFα, transforming growth factor-α.
Modified with permission from Nat Rev Cancer, Yarden and Pines, copyright 2012 (16)
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2. Overview of HER2-positive breast cancer

HER2+ breast cancer accounts for 15-20% of all breast cancer cases and is
characterized by the amplification/over-expression of HER2 gene/protein (17, 30). In
breast cancer, about 97% of cases with over-expression of HER2 protein were due to
gene amplification (17, 31-33). Normally, HER2 is expressed at a low level on the
surface of epithelial cells and is necessary for the normal development of many tissues,
including those of the breast. In contrast, breast cancer cells can have up to 25-50
copies of the HER2 gene and up to 40-100 fold increase in HER2 protein expression
which results in up to 2 million HER2 receptors per cell (27, 31, 32). This overexpression of HER2 drives continuous cell growth, proliferation and provides the cells
survival advantages. These characteristics account for aggressive phenotype and poor
prognosis of HER2+ breast cancer (Figure 3) (30, 34, 35). On the other hand, breast
cancer with HER2 over-expression is unresponsive to endocrine therapy, and tends to
metastasize to the brain (17, 27).
HER2 amplification is, however, not an indication of the late stage breast cancer
(27). Several analyses from human breast tumors demonstrated that there was no
significant difference in the levels of HER2 amplification/ over-expression among noninvasive disease, invasive disease, nodal metastasis and distant metastasis (33, 3638).

3. Methods of identifying HER2 positivity
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HER2 status is currently assessed by immunohistochemical (IHC) and/or in situ
hybridization (ISH) analysis (17, 39-41). IHC evaluates HER2 protein expression, while
ISH defines HER2 gene copy numbers using a DNA probe which can be coupled to a
fluorescent (FISH) (Figure 5) (40). However, approximately 20% of current HER2
testing may be inaccurate and there was significant variation among different
laboratories (39). Therefore, the American Society of Clinical Oncology (ASCO) and the
College of American Pathologists (CAP) have recommended guidelines in HER2
testing to ensure accuracy (42).
Briefly, breast cancer specimens initially undergo HER2 testing by a validated
IHC assay (ie, HercepTest, Dako, Glostrup, Denmark) for HER2 protein expression
(Figure 6) (39, 40). The scoring method for HER2 expression is based on the cell
membrane staining pattern which gives the result of positive, equivocal or negative IHC
(42).
If breast cancer specimens were scored with equivocal IHC (2+), the samples
should then undergo validation using single-probe ISH assay (Figure 7) (42).
If the single-probe ISH raises an equivocal score, a dual-probe ISH assay will be
performed. Dual-probe ISH use probes to detect both HER2 copies and the centromere
of chromosome 17 (chromosome enumeration probe 17, CEP17), which allows the
determination of the HER2:CEP17 ratio (Figure 8) (41, 42).
In general, FISH testing gives more reliable results than IHC does, but it is more
expensive (17). Other alternative methods for validating HER2 status, including reverse
quantitative real-time polymerase chain reaction (qRT-PCR), have not yet been widely
validated (40). For more complete views on the identification of HER2 positivity and
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clinical challenges of each technique, readers are referred to recent reviews by Hanna
et al (2014) and Perez et al (2014) (40, 41).
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Figure 5. Detection of HER2 positivity in human specimens analyzed by different
methods.

(a) IHC showing clusters of HER2-positive cells (brown staining).
(b) Double FISH/IHC staining showing the tumor cells displaying both HER2 protein
over-expression (green membrane staining) and HER2 gene amplification (red signals).
(c) Tumor analyzed by dual-probe ISH assay (HER2, black staining; CEP 17, red
staining).
Abbreviations: CEP17, chromosome enumeration probe 17; FISH, fluoresecent in situ
hybridization; IHC, immunohistochemistry; ISH, in situ hybridization.
Adapted with permission from Mod Pathol, Hanna, Rüschoff, Bilous, Coudry, Dowsett,
Osamura, Penault-Llorca, and van de Vijver, Viale, copyright 2013 (41)
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Figure 6. ASCO/CAP recommendations for evaluation of HER2 protein
expression by IHC assay

Adapted with permission from J Clin Oncol, Wolff, Hammond, Hicks, Dowsett,
McShane, Allison, Allred, Bartlett, Bilous, Fitzgibbons, Hanna, Jenkins, Mangu, Paik,
Perez, Press, Spears, Vance, Viale, and Hayes, copyright 2013 (42)
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Figure 7. ASCO/CAP recommendations for evaluation of HER2 gene amplification
using single-probe ISH assay.

Adapted with permission from J Clin Oncol, Wolff, Hammond, Hicks, Dowsett,
McShane, Allison, Allred, Bartlett, Bilous, Fitzgibbons, Hanna, Jenkins, Mangu, Paik,
Perez, Press, Spears, Vance, Viale, and Hayes, copyright 2013 (42)
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Figure 8. ASCO/CAP recommendations for evaluation of HER2 gene amplification
using dual-probe ISH assay.

Adapted with permission from J Clin Oncol, Wolff, Hammond, Hicks, Dowsett,
McShane, Allison, Allred, Bartlett, Bilous, Fitzgibbons, Hanna, Jenkins, Mangu, Paik,
Perez, Press, Spears, Vance, Viale, and Hayes, copyright 2013 (42)
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4. HER2 targeted treatment for HER2-positive breast cancer

The discovery of HER2 over-expression and its role in driving breast cancer
progression led to numerous efforts to develop agents targeting HER2 and the other
members of HER family. Currently in clinical use, approaches that target HER2 can be
divided into 3 major types: monoclonal antibodies, drug-conjugated antibodies (DCAs),
and small molecular tyrosine kinase inhibitors (TKIs) (Figure 9) (43).
Monoclonal antibodies bind to and prevent HER2 dimerization with itself or with
other receptor tyrosine kinases (RTKs). The first targeted therapy which was approved
by the Food and Drug Administration (FDA) was the humanized monoclonal antibody
called trastuzumab (43). Clinical studies have shown that combinations of trastuzumab
with standard chemotherapy produce far better response rates than does
chemotherapy alone. The triumph of trastuzumab gave rises to another FDA-approved
monoclonal antibody called pertuzumab and a FDA-approved DCA called T-DM1 (43).
T-DM1 consists of 1 molecule of trastuzumab which is covalently linked to 3 or 4
molecules of emtansine (DM) (Figure 9). DM alone is too toxic to be used in patients.
However, T-DM1 targets this toxic compound specifically to HER2-over-expressing
cells and thus spares the cells with low HER2 over-expression (43). In clinical setting,
T-DM1 has been shown to increase progression-free survival and overall survival in
patients with HER2+ advanced breast cancer. Moreover, T-DM1 showed a more
favorable toxicity profile compared with trastuzumab plus docetaxel (43). For detailed
information on T-DM1, including its activity, safety, and clinical trials, please see
reviews of LoRusso’s and Boyraz’s (2011 and 2013, respectively) (44, 45).
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TKIs are small molecules that can cross the cellular membrane and bind to the
ATP-binding pocket of kinase receptors to inhibit their catalytic activities (Figure 9) (46).
However, TKIs are far less specific than therapeutic antibodies and may be associated
with a higher risk of toxicity. The first TKIs approved by the FDA for HER2+ metastatic
breast cancer was lapatinib (46). Lapatinib potently inhibits the kinase activity of both
HER1 and HER2. Besides lapatinib, other TKIs that are in active clinical trials are
afatinib (BIBW-2992) and neratinib (HKI-272) (Figure 9). For more information on TKIs
and related clinical data, please refer to Vu et al (2014) (46).
In my studies, I focused on the effects of trastuzumab in HER2+ breast cancer.
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Figure 9. HER2 targeted therapy currently used in clinical practice for HER2positive breast cancer.

There are currently 3 main approaches to inhibiting HER2 and its family members: 1)
Monoclonal antibodies, including trastuzumab and pertuzumab to inhibit HER2
dimerization; 2) Small molecule tyrosine kinase inhibitors (lapatinib, neratinib, and
afatinib) to inhibit HER2 kinase activity; and 3) drug-conjugated antibodies to
selectively target toxic compounds to breast cancer cells over-expressing HER2.
Modified with permission from Biochim Biophys Acta, Vu and Claret, copyright 2014
(43)
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5. Impacts of trastuzumab in patients with HER2-positive breast cancer

5.1. The clinical impacts of trastuzumab in women with early HER2-positive
breast cancer

Trastuzumab has proven synergism with a variety of chemotherapeutics on
women with early HER2+ breast disease. In adjuvant (postoperative) setting, results
from 5 large trials (HERA, FinHer, NSABP B-31, BCIRG006, N9831) have
demonstrated that the addition of trastuzumab consistently reduced the risk of
recurrence up to 50% and improve overall survival up to 30% (43, 46-50).

5.2. The clinical impacts of trastuzumab on women with HER2-positive metastatic
breast cancer

In the metastatic setting, trastuzumab monotherapy was well-tolerated and
resulted in objective response rate up to 34% for a median duration of 9 months (51,
52).
Later, a pivotal phase III trial compared standard chemotherapy alone
(doxorubicin/epirubicin and cyclophosphamide or paclitaxel) with chemotherapy plus
trastuzumab in patients with HER2+ metastatic disease. The findings demonstrated
that compared with chemotherapy alone,

trastuzumab plus chemotherapy was

associated with significant improvements in time to disease progression (7.4 months vs
4.6 months), objective response rate (50% vs 32%), survival (median survival, 25.1 vs.
20.3 months), and a 20% reduction in the risk of death (53).
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Furthermore, trastuzumab in combination with other HER2-targeted therapies
such as lapatinib and pertuzumab have been shown to critically prolonged disease-free
survival time and improve overall survival in patients with HER2+ metatstatic breast
cancer (54-58).

5.3. Side effects of trastuzumab

Trastuzumab

is

relatively

non-toxic,

especially

when

compared

with

chemotherapy (59). Whereas diarrhea and rash are the common side effects, the most
serious effect of trastuzumab is cardiac dysfunction. Yet this symptom can be improved
by using the standard medical management or by adjusting the dose and duration of
trastuzumab (17, 49, 53, 59, 60).
In early clinical studies with trastuzumab, cardio-toxicity was observed in a small
percentage of patients, though this toxicity was more notable in patients concurrently
given anthracyclines (53). Therefore, it is recommended that trastuzumab should not
be combined with anthracyclines for the treatment of patients with HER2+ breast
tumors.

MOLECULAR MECHANISMS OF ACTIONS OF TRASTUZUMAB

Trastuzumab prevents HER2 activation, thus inhibits HER2-driven cell growth
and proliferation through 2 well-studied mechanisms: (1) facilitating HER2 degradation
(61) and (2) down-regulating PI3K/ AKT/ PTEN and Src pathways (Figure 10) (62). My
studies focus on the effects of trastuzumab on these pathways.
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Figure 10. Effects of trastuzumab on the downstream cascades of HER2
activation.

Upon HER2 dimerization and activation, PI3K is triggered leading to an increase in the
cellular levels of PIP3. PIP3 binds to and activates other kinases, such as PDK1 and
AKT. AKT, in turn, causes rapid degradation of p27, resulting in cell survival and drug
resistance. PTEN, antagonizes HER2 signaling by de-phosphorylating PIP3 and p-Src.
Trastuzumab, by inhibiting HER2 dimerization, turns off PI3K/AKT and Src signalings,
promotes PTEN function, and subsequently inhibits cell proliferation and tumor
progression. Smooth lines represent direct effects; dash lines represent indirect effects.
Abbreviations: AKT, protein kinase B; PDK1, 3-phosphoinositide-dependent protein
kinase-1; PI3K, class IA phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5 biphosphate; PIP3, phosphatidylinositol 3,4,5 tri-phosphate; PTEN, phosphatase and
tensin homolog deleted on chromosome 10.
Modified with permission from Oncogene, Keniry and Parsons, copyright 2008 (63)
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1. PI3K/AKT/PTEN and Src signaling – The major downstream cascades of HER2
activation

1.1. PI3K/AKT pathway

 Class I phosphatidylinositol 3-kinases (PI3Ks)
PI3Ks are heterodimers composed of p110 catalytic and p85 regulatory subunits
(Figure 10) (64).
In response to HER2 dimerization and activation, PI3K is recruited to the
membrane by direct interaction of its p85 subunit with activated HER2s. The interaction
activated p110 catalytic which in turn phosphorylates phosphatidylinositol 4,5 biphosphate

(PIP2)

at

the

3-position

of

the

inositol

ring,

converting

it

to

phosphatidylinositol 3,4,5 tri-phosphate (PIP3). PIP3 acts as a docking site for proteins
that contain the pleckstrin homology domain, such as the protein kinase B (AKT) and 3phosphoinositide-dependent protein kinase-1 (PDK1) (Figure 10) (64).
The PI3K pathway is frequently activated in human cancer which provides the
cancer cells survival and proliferation advantages (65, 66). For a comprehensive review
about PI3K regulation and function, readers are referred to Liu et al (2009) (64).

 Protein kinase B (AKT)
AKT, a serine–threonine kinase, is the key effecter of PI3K signaling in cancer
(63). Once PIP3 is generated by PI3K, AKT is translocated to the membrane and dock
its pleckstrin homology domain to PIP3 (Figure 10) (64, 67). The resulting
conformational change in AKT at the membrane allows AKT to be phosphorylated at
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serine 473 (S473) and get fully activated (68, 69). Once AKT has been activated, it can
phosphorylate other target proteins, including p27, which results in rapid p27
degradation (Figure 10) (64, 70). p27 is a critical component of the cell-cycle machinery
which controls cells’ exit from G1 phase and entry into S phase during development
and tumorigenesis (71). Therefore, activated AKT potently promotes cell cycle
progression and subsequently cell proliferation (70, 72).
Increase in AKT activation which is reflected through the increase in p-AKTS473 has been found to be correlated with HER2 over-expression in human breast
carcinoma. Moreover, AKT activation is the direct consequence of activating mutation
in PI3K or through the loss of function of the tumor suppressor gene, PTEN (64).

1.2. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN)

 PTEN structure
The PTEN tumor suppressor gene, also referred to as MMAC (mutated in
multiple advanced cancers), was identified by homozygous deletion mapping of the
human chromosome 10q23 in cancer (73, 74). PTEN protein contains 403-amino acid
which has dual-specific tyrosine and lipid phosphatase functions (74, 75).
PTEN structure is composed of 4 domains: the PIP3 binding domain (PBD), the
phosphatase domain, the C2 domain and the C-terminal tail (Figure 11) (75). The
extreme N terminus of PTEN resides in the PBD which is essential for membrane
localization and PTEN catalytic activity. Next to the PBD is the phosphatase domain
which has the catalytic pocket (75). The C2 domain is required for PTEN to bind to the
phospholipid membranes (76). The phosphatase and C2 domains together make up
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the minimal catalytic region of PTEN (75, 77). The C-terminal tail, which contains a
PDZ (PSD-95, Discs-large, ZO-1)-binding domain, is important for the regulation of
PTEN stability and its interaction with other proteins (75, 76, 78, 79).
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Figure 11. Schematic representation of PTEN structure and function.

(a) PTEN contains 4 distinct domains: the PBD, the phosphatase domain, the C2
domain and the C-terminal tail with the PDZ motif.
(b) PI3Ks phosphorylate PI(4,5)P2 to generate PI(3,4,5)P3. PTEN antagonizes PI3Ks
effect by removing phosphate group on PI(3,4,5)P3 and converting it back to PI(4,5)P2.
Modified with permission from Nat Rev Drug Discov, Liu, Cheng, Roberts, and Zhao,
copyright 2009 (64)
Abbreviations: PBD, PIP3 binding domain; PDZ (PSD-95, Discs-large, ZO-1)-binding
domain.
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 PTEN functions as a lipid phosphatase
The lipid phosphatase function of PTEN is regulated through its binding to the
plasma membrane (75, 79, 80). The association step results in a conformational
change of PTEN and activation of its phosphatase domain to convert PIP3 to PIP2
(Figure 11) (77, 80, 81). The trigger for PTEN dissociation is unknown.
The PIP3 generated by PI3Ks, is therefore, tightly regulated by PTEN (77, 81).
The biological link between the PI3K pathway and PTEN was demonstrated by the
finding that deletion of PTEN elevated intracellular PIP3 levels and thus activated AKT
in numerous cell types including breast cancer cells (77, 81-83). Therefore, the loss of
PTEN results in unrestrained signaling by the PI3K/AKT pathway (81). As such, PTEN
with its lipid phosphatase function negatively regulates many cellular processes,
including cell proliferation and survival (Figure 10) (63, 81).

 PTEN functions as a tyrosine phosphatase
PTEN is well-studied for its lipid phosphatase function, yet there are few
research investigating the regulation of PTEN tyrosine phosphatase. It was recently
found that in breast cancer cell lines, PTEN loss was associated with an increase in the
phosphorylation of the oncogenic Src at tyrosine 416 (Y416). The study also
demonstrated that PTEN and Src proteins interacted and that PTEN de-phosphorylated
p-Src-Y416 peptide in vitro (84).

 Post-translational regulation of PTEN stability
The activity of PTEN is regulated at many levels, including DNA methylation,
transcriptional regulation, micro-RNA-directed mRNA degradation, posttranslational
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modifications (phosphorylation and ubiquitination) or through protein-protein interaction
(Figure 12) (63, 85, 86). These mechanisms are modulated to maintain appropriate
PTEN activity, thereby regulating the cellular content of PIP3, p-AKT and p-Src (86,
87).
In my studies, I focused on the post-translation regulation of PTEN, specifically
through phosphorylation and ubiquitination.
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Figure 12. Regulation of PTEN stability and function by different mechanisms.

PTEN can be regulated through epigenetic modification such as DNA methylation of
PTEN promoter. At the transcriptional level, PTEN can be regulated by multiple
transcription factors. PTEN mRNA can also be mediated by micro-RNA. The posttranslational regulation of PTEN includes protein-protein interaction, ubiquitination,
oxidation, and phosphorylation which affect the activity and function of PTEN.
Adapted with permission from Trends Pharmacol Sci, Leslie and Foti, copyright 2011
(85)
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Regulation of PTEN through phosphorylation

Under normal condition, PTEN exists in the “closed” conformation in the
cytoplasm, in which, its C-terminal tail “masks” the C2 domain (Figure 13) (78, 88). This
C-tail contains a cluster of serine and threonine residues, which are phosphorylated by
casein kinase 2 (89). Specifically, phosphorylation of serine 380 (S380), threonine
3802/383 (T382/383) in the C-tail of PTEN appears to keep PTEN in the “closed” and
less active state (78, 90). De-phosphorylation or alanine mutation of these sites
(S380A, T382A, and T383A) “opens” PTEN and leads to its translocation to the
membrane (80, 90). The “open” conformation results in an elevation in PTEN lipid
phosphatase activity yet provokes a decrease in PTEN's stability, in comparison with
“closed” PTEN (Figure 13) (78, 80, 90).


Regulation of PTEN by poly-ubiquitination

Many studies have currently supported a dominant role of the ubiquitin
proteasome pathway in controlling PTEN's stability (Figure 13). They found that
treatment of cancer cells with proteasome inhibitors enhanced the levels of PTEN
protein. Also, several E3 ligases for PTEN have been proposed (86, 87). Three such
candidates are NEDD4-1 (neural precursor cell-expressed developmentally downregulated protein 4), WWP2 (WW domain-containing protein 2), and XIAP (X-linked
inhibitor of apoptosis protein). NEDD4-1 is the first proposed E3 ligase for PTEN and
promotes PTEN degradation through ubiquitin-proteasome system in non-small cell
lung cancer (Figure 13) (91, 92). Moreover, NEDD4-1 was found to facilitate PTEN
mono-ubiquitination which mediates PTEN import to the nucleus (91, 93). However, the
exact mechanism and the nucleus function of PTEN regulated by NEDD4-1 are
unclear. WWP2, a NEDD4-like E3 ubiquitin ligase, was found in a pull-down analysis
33

for interacting partners of PTEN. Endogenous WWP2 interacts with and polyubiquitylates PTEN, then targets PTEN for degradation (94). XIAP is a member of the
inhibitor of apoptosis family of proteins, was discovered to regulate PTEN polyubiquitination and degradation in breast cancer (95). Interestingly, the group who
discovered WWP2 could not confirmed the previous conclusion that NEDD4 was an E3
ligase for PTEN (94). Therefore, it seems that much remains to be discovered
regarding how PTEN ubiquitination is controlled and if it is cell context dependent.
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Figure 13. Regulation of PTEN function and activity by phosphorylation and
ubiquitination.

Cytosolic phosphorylated PTEN is stable but display minimal activity. Once PTEN is
de-phosphorylated and recruited to the membrane, PTEN is more active but less stable
compared to the cytosolic PTEN. On the other hand, PTEN turnover can be regulated
by ubiquitination, specifically through interacting with an E3 ligase, NEDD4-1. Polyubiquitylated PTEN remains in the cytoplasm and is targeted for degradation by the
proteasome, whereas mono-ubiquitination of PTEN translocates PTEN into the
nucleus, where its function remains unclear.
Abbreviation: NEDD4-1, neural precursor cell-expressed developmentally downregulated protein 4; P, phosphor group; Ub, ubiquitin.
Adapted with permission from Annu Rev Pathol, Chalhoub and Baker, copyright 2009
(87)
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 The loss of PTEN in breast cancer
The importance of PTEN in cellular function is underscored by the frequency of
its aberrant expression in various cancer types (63, 87).
PTEN mutation is most frequent in endometrial cancers, approximately 50%
(~50%). However, only ~5% of PTEN is mutated in breast cancer (73, 87). On the other
hand, PTEN protein is lost or reduced in about 48% of human invasive breast
carcinoma which is correlated with poor prognosis (96, 97). In HER2+ breast cancer,
low expression of PTEN is seen in ~25% of all cases (98). The other group found that
the loss of PTEN was observed in 36% of HER2+ breast cancer patients with stage IV
disease (99).
It is interesting to note that, no germline or somatic mutations have been
detected specifically in the phosphorylation cluster (S380/T382/383) at the C-tail of
PTEN (100). There are two proposed explanations for these observations. One
hypothesis is that the presence of dominant negative mutations within PTEN tail is
embryonic lethal. The other hypothesis is that these mutations are not germane to
carcinogenesis (100).
In general, given the important role of PTEN in tumor progression, subtle
variation in PTEN expression has been experimentally demonstrated to have
significantly impacts on tumor susceptibility and progression (Figure 14) (101, 102).

36

Figure 14. Correlation of PTEN expression levels and tumorigenesis.

Complete or partial loss of PTEN differently affects the outcomes of breast cancer.
Abbreviations: PD, poorly differentiated; WD, well-differentiated.
Modified with permission from Nature, Berger, Knudson, and Pandolfi, copyright 2011
(102)
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1.3. Src

Src is a protein product of c-Src (Src) gene belongs to the Src family of kinases
(SFKs), a group of non-RTKs. The Src gene, discovered in the 1970s, is the oldest
‘proto-oncogene’ in mammalian cells (103).
The most well-studied function of Src is its interaction with activated
transmembrane RTKs, including activated HER2 (103-105). Through its interactions,
Src directly transduces survival signals to downstream effectors such as PI3Ks and
AKT (105). Therefore, Src is a potent transforming and tumorigenic factor and its
activation is seen in many human tumor types, including HER2-over-expressing breast
cancer (103).
For comprehensive reviews about Src regulation and function, readers are
referred to Yeatman (2004) and Zhang et al (2012) (103, 105).

2. Molecular effects of trastuzumab on PI3K/AKT/PTEN and Src signaling

A well-known proposed mechanism of trastuzumab action is the elevation in
PTEN function accompanied by the reduction in PI3K/AKT and Src signaling.
Several groups have demonstrated that trastuzumab specifically disrupts HER2Src interactions, leading to inactivation of Src. This, in turn, causes increased PTEN
phosphatase activity which results in de-phosphorylating AKT at S473 and Src at Y416.
Moreover, by inhibiting HER2 activation, trastuzumab abolished HER2-activated PI3K
activity, which also reduces p-AKT-S473 level (table 2).
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Table 2. Molecular effects of trastuzumab on the expression levels of
PI3K/AKT/PTEN and Src.

HER2 activation

Trastuzumab treatment

PI3K

p-AKT-S473

p-Src-Y416

PTEN
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MECHANISM OF TRASTUZUMAB RESISTANCE

1. Overview of trastuzumab resistance

Though trastuzumab with or without chemotherapy has significantly prolonged
patients’ survival, data from large randomized trials showed that about 50% of patients
did not respond to trastuzumab with anthracycline and cyclophosphamide (53). Also,
about 74% of patients did not experience a response to first-line trastuzumab
monotherapy (52). This can be referred to as primary resistance (43).
Moreover, secondary resistance to trastuzumab eventually developed in a large
number of patients who initially responded (43). In an adjuvant setting, about 70% of
patients with early-stage HER2+ breast cancer relapse after one year of initial
treatment (47).
Despite numerous studies trying to identify the resistant mechanism and find
ways to overcome it, the molecular mechanisms underlying the resistance are not well
defined. Some of the compensatory pathways and downstream signaling aberrations
such as loss of PTEN function or increase in Src activation have been implicated.

2. The loss of PTEN and the constitutive active AKT in conferring trastuzumab
resistance

Nagata and colleagues (2004) was the first to show that patients with PTENdeficient tumors had markedly lower overall response rates to trastuzumab plus taxane
than did patients with wild-type PTEN (35.7% vs. 66.7%) (99). The group also find that
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the loss of PTEN which led to constitutive active AKT significantly contributed to both
inherent and acquired resistance to trastuzumab (99). Later, other group demonstrated
that in tumor specimens from metastatic breast cancer patients who were treated with
trastuzumab, the loss of PTEN was significantly correlated with the poor response rate
to this therapy (106). In contrast, restoration of PTEN expression suppressed tumor
formation and progression and enhanced the anti-proliferative function of trastuzumab
(83, 98, 107).

3. The role of Src in promoting trastuzumab resistance

Zhang and colleagues (2011) were the first to identify that Src signaling was
significantly up-regulated in both primary and acquired trastuzumab resistance.
Furthermore, they found that PTEN deficiency also led to Src hyperactivation which in
turn promoted trastuzumab resistance (84). However, the correlation between Src
activation and trastuzumab resistance has not been supported in clinic, and the trials
using Src inhibitor in combination with trastuzumab have not yielded any significant
results.

JAB1

1. Overview of Jab1 and its structure

Jab1 (c-Jun activation domain-binding protein-1) protein, encoded by a COPS5
gene, was initially identified as a coactivator of c-Jun, a transcription factor involving in
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numerous cellular processes, such as cell proliferation and tumorigenesis (108, 109).
Later, Jab1 was discovered to be the fifth component of the photomorphogenic-9
(COP9) signalosome (CSN) complex which was called CSN5. CSN is a large protein
complex which regulates multiple cellular processes in both mammalian and plant cells
(110). To date, more than 20 proteins have been identified to interact with Jab1,
including other CSN subunits, which suggest the diverse roles of Jab1 in regulating
cellular processes (109, 111).
Jab1 protein contains 3 distinct domains, namely c-Jun binding domain (JBD),
Mpr1-Pad1-N-terminal (MPN) domain and the C-terminal domain (Figure 15) (109,
112). The MPN domain has the metalloenzyme motif (JAMM) which is essential for
mediating Jab1 interaction with other proteins and for its isopeptidase activity (110112).
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Figure 15. Jab1 structure.

Jab1 protein is of 334-amino-acid long with 3 identified domains: JBD domain, MPN
domain and unidentified C-terminal domain. Within the MPN domain, positions of the
residues forming the JAMM motif are indicated by red lines.
Abbreviations: JAMM, JAB1/MPN/Mov34 metalloenzyme; JBD, c-Jun binding domain;
MPN, Mpr1p, Pad1p-N-terminal.
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2. Jab1 as a coactivator of c-Jun

Jab1 potently enhances the transcriptional function of c-Jun by physically
interacting with c-Jun protein (Figure 16) (108). c-Jun is a well-studied oncogene
whose aberrant expression and activity have been detected in numerous cancer,
including breast tumors. Over-expression of Jab1, therefore, aggressively drives c-Jun
activity to promote tumorigenesis (Figure 16) (108).

3. Jab1 as a negative regulator of p27

Jab1 directly binds to p27 and induces its nuclear export and subsequent
degradation (Figure 16) (113, 114). Our group previously examined the relationship
between Jab1 and p27 and their association with prognosis in clinical specimens of
invasive breast carcinoma (115, 116). We found that in the group of tumors that had
elevated Jab1 protein levels, p27 protein expression was significantly down-regulated
(p = 0.02). Moreover, we noticed that breast tumors with high p27 and low Jab1 protein
expressions showed better prognosis compared with tumors with low p27 and high
Jab1 protein levels. The correlations between reduced expression of p27 and overexpression of Jab1 were also observed in other human tumors and were
comprehensively reviewed by Shackleford and Claret (2010) (109). These findings
confirm that Jab1 is a potent negative regulator of p27 in different cancer types.

4. Jab1 as a member of the CSN with isopeptidase activity
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The CSN is a multisubunit complex located mainly in the nucleus and a regulator
of various cellular and developmental processes, including cell-cycle control,
transcription, and DNA-damage response (110, 117). The CSN consists of 8 subunits,
namely CSN-1, -2, -3, 4, -5, -6, -7 and -8 in mammals (109, 117).
Jab1 is one of two members of the CSN that contains the MPN domain (the
other one is CSN6) (110-112). Jab1 MPN domain contains a metalloprotease motif
referred to as JAMM (Jab1/MPN/Mov34 metalloisopeptidase) or MPN+ motif (Figure
15) (118). The MPN domain of CSN6 does not contain a JAMM motif (110, 111, 117).
The JAMM motif is involved in zinc ion coordination and provides the active site
for isopeptidase activity. JAMM motif can catalyze ubiquitin from ubiquitinated proteins
that are tagged for degradation (110, 112, 117, 118). Thus, Jab1 with JAMM motif was
proposed to have deubiquitinating activity; yet it has not been experimentally validated
(111). Mutations in the conserved histidine (His) or aspartic acid (Asp) residues of the
Jab1/JAMM motif abolish this activity (110, 118, 119).

5. The role of Jab1 in cancer progression

Besides p27, Jab1 can mediate the nuclear export and cytoplasmic degradation
of the tumor suppressor p53 (Figure 16) (120, 121). Through these mechanisms, Jab1
over-expression has been demonstrated to drive cell proliferation, inhibit apoptosis, and
impair cellular DNA damage repair (109, 121, 122).
Transgenic mouse model with over-expression of Jab1 showed enhanced
proliferation (123). In contrast, inhibition of Jab1 resulted in delayed tumor growth in
murine xenografts (124).
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Moreover, analysis from specimens of patients with invasive breast carcinoma
showed that Jab1 expression was elevated in 50% of primary breast tumors and 90%
of metastatic lesions. However, its expression is low or absent in normal adult breast
tissue (116).
In conclusion, Jab1, through working as part of the CSN holocomplex and
independently of the CSN, promotes cell growth and survival (Figure 16). Furthermore,
high expression of Jab1 was associated with poor outcome in breast cancer patients.
For comprehensive summary of Jab1 activity, its target proteins and its role as a part of
CSN complex, please refer to Wei et al (2008) and Terry et al (2010) (109, 110).
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Figure 16. Simplified model of direct targets and functions of Jab1.

Jab1 was first discovered to bind to and enhance c-Jun transcription function. Later,
Jab1 was found to associate with and promote rapid degradation of p27 and p53
through proteasomal pathway. With these functions, Jab1 potently facilitates tumor cell
growth and proliferation.
Green arrows and plus (+) signs indicate Jab1-positive interaction; red arrows and
minus (-) signs indicate Jab1-negative interaction.
Modified from Cell Div, Shackleford and Claret, 2010 (109)
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TWO MAJOR MECHANISMS TO DEGRADE INTRACELLUALR PROTEINS

Protein degradation, as well as synthesis, is essential to normal activity of the
cell. To degrade intracellular proteins, all eukaryotic cells have two major mechanisms,
namely the ubiquitin–proteasome system (UPS) and the lysosomal proteolytic pathway
(125). The proteasome mainly degrades ubiquitinated proteins. The lysosomal
proteolytic pathway, in contrast, does not require protein to be ubiquitinated for
degradation and can degrade other macromolecules and cell organelles.

THE LYSOSOMAL PROTEOLYTIC PATHWAY AND PROTEIN DEGRADATION

1. Overview of the lysosomal proteolytic pathway

Lysosomes are acidic (pH 4.5–5) catabolic organelles found in all mammalian
cells except for mature erythrocytes. The lysosome is often described as a ‘‘cellular
garbage can’’ that is responsible for the disposal and recycling of old-age or damaged
cellular macromolecules and organelles (Figure 17). After the targets are digested by
lysosomal enzymes, the products are recycled back to the cytosol via diffusion and
specific transport channels or released to the extracellular space by exocytosis (Figure
17) (126).
Lysosomes

contain

more

than

50

hydrolases

including

proteinases,

phosphatases, nucleases, and lipases, which function only in the highly acidic pH
inside the lysosomal lumen (126).
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Lysosomal membrane components are not well characterized (126). In general,
they are composed of integral membrane protein 2 (also known as SCARB2), vacuolar
proton pump ATPase (VP-ATPase), transport proteins, and membrane-associated
proteins such as lysosomal-associated membrane proteins 1 and 2 (LAMP-1 and
LAMP-2). VP-ATPase is ubiquitously expressed and drives protons against their
electrochemical gradient into the lysosome in an ATP-dependent manner. VP-ATPase
is critical for the maintenance of acidic pH inside lysosome (126). LAMP-1 and LAMP2, single span transmembrane proteins, make up approximately 50% of the lysosomal
transmembrane proteins and play pivotal role in maintaining the structural integrity of
the lysosomal compartment. In addition, LAMPs also regulate lysosomal trafficking and
exocytosis (126).
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Figure 17. The role of the lysosome in clearing cytosolic components.

Accumulated macromolecules or damaged organelles are delivered to lysosome for
degradation. Lysosome can break down proteins, lipid, and glycogen for the synthesis
of new proteins and production of energy. Levels of amino acids, free fatty acids, and
sugars circulating in blood or in the extracellular media have a direct impact on the
function of lysosome.
Adapted with permission from Cell Metab, Singh and Cuervo, 2011 (127)
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Currently, there are three basic ways to deliver substrates to lysosome for
degradation (128). They are macro-autophagy (or autophagy), micro-autophagy, and
chaperone‑mediated autophagy (CMA) (Figure 18). Two of them, autophagy and
micro-autophagy, are high-capacity processes that can directly sequestered multiple
cytosolic components (soluble proteins and organelles) and degrade them in the
lysosomal lumen. In contrast, CMA only modulates the lysosomal degradation of
specific cytosolic proteins on a one-by-one basis (128). The three pathways and their
comprehensive physiological and pathological relevance have been extensively
reviewed in Sridhar et al (2012), Mizushima et al (2011) (128, 129).
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Figure 18. Three major types of the lysosomal proteolytic pathway.

Macro-autophagy (autophagy) is characterized by the formation of autophagosome
which then fuses with the lysosome to form autolysosome where all internal materials
are degraded. In micro-autophagy, small pieces of the cytoplasm are directly engulfed
by inward invagination of the lysosomal membrane. Chaperone-mediated autophagy,
the most selective form, only degrades proteins and is mediated by the cytosolic Hsc70
and the lysosomal membrane LAMP-2A. After all, resultant degradation products can
be used for new protein synthesis, energy production, and gluconeogenesis.
Abbreviations: Hsc70, heat shock cognate protein of 73 kDa; LAMP-2A, lysosomalassociated membrane proteins.
Adapted with permission from Cell, Mizushima and Komatsu, 2011 (129)
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2. Macro-autophagy (autophagy)

2.1. Overview of autophagy

Autophagy, the most well-studied form of lysosomal proteolytic pathway, is an
essential physiological process for cell survival during starvation (Figure 18) (129).
Autophagy was first described as mechanisms for ‘in bulk’ degradation.
However, emerging evidence suggests that there is selective form of autophagy,
specifically in degrading intracellular proteins, which will be described below. In the
selective autophagy, ubiquitinated protein are recognized by a specific subset of
proteins known as cargo-recognition proteins such as p62 (also known as
sequestosome 1) (128, 130, 131).
Genetic screenings of autophagy in yeast have identified that more than 30
different genes (known as ATGs or autophagy-related genes) participate in the
execution and regulation of macroautophagy. Among them, ATG1–10, 12–14, 16, and
18 are considered the ‘‘core ATG proteins’’ and are required for autophagosome
formation (129, 132-135).

2.2. The selective autophagy process

Autophagy is a multi-step process to degrade a substrate protein which can be
divided

in

three

autophagosome

main

steps:

formation

and

(1)

initiation

substrate

and

phagophore

sequestration,

and

formation,
(3)

(2)

fusion

of

autophagosome and lysosome and the degradation of the substrates (127, 129, 134).
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 Initiation and phagophore formation
Cellular stresses, including reactive oxygen or reactive nitrogen species (ROS,
RNS), or nutrition starvation activate AMP-activated protein kinase (AMPK) and inhibit
mammalian target of rapamycin (mTOR) to signal autophagy through ATG1-containing
complex (127). Once initiated, a kinase complex formed by Beclin-1 (autophagy-related
Bcl2-interacting ATG6 homolog) and VPS34 (vacuolar protein sorting 34) triggers
downstream events leading to activation and formation of ATG12/ATG5 complex (127,
133, 134). The resulting ATG12/ATG5 conjugate forms a complex with a homodimer of
ATG16, which assembles on a membrane structure termed the phagophore or isolation
membrane (Figure 19) (127, 132-134).

 Autophagosome formation and substrate sequestration
After the phagophore is formed, ATG8 (a yeast homolog of mammalian
microtubule-associated protein light chain 3, LC3-I) is activated by cascade of other
ATG proteins. ATG8/LC3-I is then conjugated onto phosphatidylethanolamine (PE) in
the lipid bilayer of the membrane. This reaction results in the formation of lipidated
LC3-I called LC3-II or ATG8–PE, in yeast (Figure 19) (134, 136).
The growing ends of the phagophore eventually meet and fuse to form the
double-membrane structure of the autophagosome. LC3-II is present on both surfaces
of the isolation membrane (134, 136). ATG12/ATG5/ATG16 preferentially localizes on
the outer surface of the membrane and dissociates from the membrane upon
completion of the autophagosome (Figure 19) (134).
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In selective autophagy, the phagophore engulf ubiquitinated proteins through
p62 (131, 137). p62 sequesters target proteins to the autophagosome through directly
association with LC3 (137, 138). Impairment of autophagy from this step is therefore,
partially reflected by the accumulation of p62 (129, 139, 140).

 Fusion of autophagosome and lysosome and the degradation of target substrate
Autophagosome finally fuses with a lysosome to form autolysosome. Inside
autolysosome, the infusion of hydrolases and the acidification results in the complete
degradation of cargo into their constituent components, including LC3-II and p62 as
well as p62-conjugated proteins (135).
The acidification is mediated by the VP-ATPase. Inhibition of the activity of VPATPase by bafilomycin A or concanamycin A blocks the lysosomal pumping of H+
resulting in less acidic pH environment and inhibiting functions of lysosomal enzymes
(Figure 19) (140). Importantly, it was also proposed that bafilomycin A also blocks the
fusion of autophagosomes with lysosomes though the mechanism is not fully
understood. In general, the overall consequences of bafilomycin A is to prevent the
degradation of sequestered materials, which is reflected by the accumulation of LC3-II
and p62 (table 3) (140, 141). The summary of autophagy process is described in Figure
19.
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Figure 19. Overview of selective autophagy and its inhibition.

Autophagy is triggered by increased ROS level leading to the formation of various ATG
complexes and subsequently autophagosome. The fussion of autophagosome and
lysosme forms autolysosome which degrades all the internal contents, including LC3,
p62 and target ubiquitinated substrates.
Abbreviations: 3-MA, 3-Methyladenine; AMPK, AMP-activated protein kinase; ATG,
autophagy-related gene; LC3, microtubule-associated protein light chain; RNS, reactive
nitrogen specifies; ROS, reactive oxigen species; Ub, ubiquitin; VP-ATPase, vacuolar
proton pump ATPase; VPS, vacuolar protein sorting.
Modified with permission from Am J Physiol Cell Physiol, Gottlieb and Carreira, 2010
(142)
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Table 3. Molecular effects of autophagy inhibition (140).

Inhibition

ATG5

of

late

Inhibition of autophagy

autophagy

initiation such as ATG5

(Bafilomycin A)

depletion

No change

Not detected

p62

LC3I/II
Not formed
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3. Micro-autophagy

Micro-autophagy is descrised as the sequestration process of a cytosolic region
directly by the lysosomal membrance. The steps involve: (1) invagination of vacuole,
(2) internalization of portions of cytsolic components, and (3) degradation of all the
components (Figure 18) (129). Micro-autophagy also involves the direct engulfment of
organelles, such as the peroxisome and the nucleus (127).
There have been some discoveries on yeast micro-autophagy. However,
mammalian micro-autophagy remains a “mysterious” process due to the absence of
mammalian homologs for the micro-autophagy genes discovered in yeast (127, 129,
143).

4. Chaperon-mediated autophagy (CMA)

4.1. Overview of the CMA

CMA is a highly selective form of autophagy that has only been described in
mammalian cells (128). CMA plays a pivotal role in removing misfolded proteins and
providing amino acids during prolonged periods of starvation. CMA is active in almost
all cells, although basal and inducible levels of CMA activity vary depending on the cell
types and cellular conditions.
Alterations of CMA have been linked to different human pathologies such as
Parkinson’s disease, and several lysosomal storage disorders (144). However, little is
known about the contribution of CMA to cancer biology. Recently, activation of CMA
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has been found in various cancer cell lines and human tumor biopsies, including breast
tumors. Moreover, suppression of CMA by knocking down LAMP-2A in lung cancer
cells significantly reduced cancer cell proliferation and tumor growth (145).

4.2. The CMA process

A protein gets degraded by CMA through five steps: (1) substrate recognition
and lysosomal targeting; (2) binding of the substrate to LAMP-2A; (3) unfolding of
substrate protein; (4) substrate translocation across the lysosomal membrane; and (5)
substrate degradation in the lysosomal lumen (Figure 20) (146). All the first four steps
take place in the cytosol.
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Figure 20. Overview of the CMA process.

CMA is a five-step process in which a protein containing the KFERQ-like motif is first
recognized by Hsc70. Hsc70 transports the protein to the LAMP-2A complex on the
lysosomal membrane. The protein is translocated across the lysosomal membrane
through LAMP-2A and lys-Hsc70; and finally gets degraded in the lysosomal lumen.
Abbreviation: lys-Hsc70, lysosomal-Hsc70.
Modified with permission from J Cell Sci, Kaushik, Bandyopadhyay, Sridhar, Kiffin,
Martinez-Vicente, Kon, Orenstein, Wong, and Cuervo, 2011 (146)
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 Substrate recognition and lysosomal targeting
A protein considered to be a CMA substrate has to contain a pentapeptide motif
in its amino acid sequence which is biochemically related to the KFERQ-like motif (147,
148). KFERQ-like motifs have been found in 30% of cytosolic proteins (144, 147). By
definition, KFERQ-like motif contains 5 types of amino acids: (1) a glutamine (Q)
residue, at the beginning or end of the sequence; (2) one of the two positively charged
amino acids, lysine (K) or arginine (R); (3) one of the four hydrophobic amino acids,
phenylalanine (F), valine (V), leucine (L) or isoleucine (I); (4) one of the two negatively
charged amino acids, glutamic acid (E) or aspartic acid (D); and (5) either a positive or
hydrophobic amino acid as the fifth one (148).
The motif is then recognized by a heat shock cognate protein of 73 kDa (Hsc70)
in the cytosol (149). Moreover, the motif must be presented on the exterior of the folded
target protein for Hsc70 to bind to it. Having multiple KFERQ-like motifs does not
increase the affinity of a substrate for the chaperone, or its rate of degradation by the
CMA.

 Binding of substrate to LAMP-2A
The substrate-chaperone complex is targeted to the lysosomal surface, where it
interacts with the cytosolic tail of LAMP-2A (Figure 20) (150).
LAMP-2A is normally present at the lysosomal membrane as monomers. To
transport the substrate across the membrane, LAMP-2A forms a multi-protein complex
(Figure 20) (151).
Binding of the substrate to LAMP-2A is a limiting step for the CMA. Levels of
LAMP-2A at the lysosomal membrane are tightly controlled and constitute a regulatory
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mechanism for the CMA (144, 152).

 Unfolding of substrate protein
Once the substrate binds to LAMP-2A, it undergoes the unfolding step which is
thought to be mediated by Hsc70 and some of its cochaperones. It is important to note
that only soluble cytosolic proteins that can be unfolded by Hsc70 and thus are
considered CMA substrates. This process is expected to be completed before the
multimer LAMP-2A complex is fully assembled (144).

 Substrate translocation across the lysosomal membrane
After unfolding, the substrate is translocated into the lysosomal lumen through
LAMP-2A which is assisted by a luminal form of Hsc70 (lys-Hsc70) (Figure 20) (144,
153). As soon as the substrate is translocated into the lumen, LAMP-2A disassembles
from its multimer complex into monomer where other substrates can bind again. The
dissociation of LAMP-2A was thought to occur in an Hsc70-dependent manner (144).
Lys-Hsc70 is not the result of internalization of (cytosolic) Hsc70 through CMA,
thought Hsc70 itself may be a CMA substrate (144, 153). This was supported by the
experiment in which blockage of CMA did not affect the content of lys-hsc70 in
lysosomes (154). Instead, Lys-Hsc70 was proposed to be internalized to the lysosomal
compartment through endosomal-lysosomal fusion (144).

 Substrate degradation in the lysosomal lumen
Once in the lysosomal lumen, the substrate is rapidly degraded (in 5–10 min) by
lysosomal proteases (Figure 20) (144).
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In conclusion, CMA is a very specific and highly regulated process of protein
degradation. From the experimental view, a substrate must be recognized and
associated with both Hsc70 and LAMP-2A to be degraded by the CMA. The
requirements for a CMA substrate are summarized in table 4 (144).
Readers interested in CMA, its regulation and its physiological as well as
pathological roles are referred to comprehensive reviews by Kaushik et al (2011) and
Cuervo et al (2014) (144, 146).
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Table 4. Requirements and methods to identify a CMA substrate.

Characteristics of CMA substrate

Assay(s)

Presence of KFERQ-like motif in the sequence

Sequence and structural analyses

Increased protein level of the target due to CMA siRNA and western blot analyses
inhibition (depletion of Hsc70 or LAMP-2A)

Association with Hsc70 and LAMP-2A

Co-immunoprecipitation

Association with LAMP-2A at the lysosomal

Co-immunoprecipitation with LAMP-

membrane

2A from isolated lysosomes
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UBIQUITIN-PROTEASOME SYTEM - A COMMON WAY TO DEGRADE CELLULAR PROTEINS

The ubiquitin-proteasome system (UPS) is considered the major pathway in
regulating protein turnover. The UPS, which accounts for the degradation of about 80%
of intracellular proteins, degrades ubiquitin-conjugated proteins by 26S proteasomes.
Substrates of the UPS include soluble proteins of the cytosol and nucleus, and proteins
of the endoplasmic reticulum that have been ejected into the cytoplasm. The process of
protein degradation by the UPS is described in details below (155).

1. Ubiquitin-conjugating machinery

1.1. Ubiquitin

Ubiquitin (Ub) is a 76-amino-acid long protein. Ubiquitination (also referred to as
ubiquitylation) is a process in which Gly76 residue of Ub is coupled to a Lys residue of
another protein through an isopeptide bond (155). A Ub itself has 7 lysine (Lys)
residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63), which means seven
possible homotypic linkage types and multiple possible heterotypic chains can be
formed (155, 156). As a result, a ubiquitinated protein can gain or lose its function
and/or be degraded, depending on the types of Ub attached to it (Figure 21) (155).

1.2. Ubiquitin conjugating cascade

The process of ubiquitin conjugation involves 3 steps (Figure 21) (155). First, Ub
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is activated through forming a covalent bond with the ubiquitin-activating enzyme (E1)
in an ATP-dependent manner. Second, E1 transfer the Ub to the ubiquitin-conjugating
enzyme (E2). Third, the ubiquitin ligase (E3) recognizes its specific substrate and
transfers Ub from the E2 to a substrate lysine to make ubiquitinated protein. The
completion of one ubiquitination cycle results in a mono-ubiquitinated substrate. The
ubiquitin chain can then be lengthened by the E2 and E3 (Figure 21). Also, the fates of
ubiquitinated proteins depend on the amount of ubiquitin added and the configuration of
the linkages (155, 157).
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Figure 21. The ubiquitin conjugating cascade.

(A) The process of protein ubiquitination involves 3 steps: (1) E1 activates Ub in an
ATP-dependent manner; (2) an E2 enzyme transfers Ub from E1; and (3) an E3
enzyme facilitates the transfer of Ub to a target protein. The substrate can be mono-,
multi- or poly-ubiquitinated through different linkages. Adapted with permission from
Nat Rev Mol Cell Biol, Dikic, Wakatsuki, and Walters, copyright 2009 (155)
(B) Three classes of E3 ligases have been identified: (i) HECT, (ii) RING, and (iii) multisubunit complexes such as the SCF complex. Adapted with permission from J Mol Cell
Cardiol, Willis and Patterson, copyright 2006 (157)
Abbreviations: HECT, homologous to E6-AP C terminus; Lys, lysine; RING, really
interesting new gene; SCF, Skp1-Cullin-F-box; Ub, ubiquitin.
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 The fates of poly-ubiquitinated proteins
Among different poly-Ub linkages, ubiquitin chains linked via Lys48 (K48) or
Lys63 (K63) are the best characterized so far (155). Whereas K48 chains are more
globular, K63 chains are more extended and elongated (Figure 21) (157). Additionally,
it is well-supported that proteins tagged with K48-linked poly-Ub represent a signal for
proteasomal degradation (156, 158, 159). In contrast, growing evidence suggest that
substrates tagged with K63-linked chain are not targeted for proteasomal degradation
(156, 160, 161). Instead, K63-linked chain affects protein localization, cellular signaling
and is currently shown to direct substrates for lysosomal degradation (143, 161-163).
However, the later mechanism is not fully understood.

1.3. Deubiquitination

The regulation and maintenance of ubiquitinated proteins is the fine tune
between the ubiquitination and the de-ubiquitination (155). The later is catalyzed by
deubiquitinating enzymes (DUBs) which cleavage Ub from ubiquitinated substrates,
especially prior to proteolysis of the proteins. Therefore, DUBs play a pivotal role in
recycling Ubs and in maintaining the sufficient pool of free Ubs. Moreover, DUBs can
also reverse the effects of ubiquitination, such as preventing protein degradation
(Figure 22) (164).
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Figure 22. Protein ubiquitination in comparison with protein phosphorylation.

Protein phosphorylation involves the covalent attachment of a phosphate (P) to
proteins, mainly through serine, threonine, or tyrosine residues. Phosphorylation is
facilitated by protein kinases and reversed by protein phosphatases.
Protein ubiquitination involves the covalent attachment of ubiquitin (Ub) to proteins
through lysine residues. This reaction is mediated by a cascade of E1, E2 and E3
enzymes. Ubiquitination process is reversed by deubiquitinase enzymes.
Adapted with permission from Cell, Cohen and Tcherpakov, copyright 2010 (164)
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2. 26S proteasome and protein degradation

The final step of a poly-ubiquitinated protein is its degradation by the 26S
proteasome, forming a complete cycle of the UPS process.
The 26S proteasome is a large 2.1 MDa complex, containing two separated
subcomplexes - the 20S core catalytic particle (CP), and the 19S regulatory particle
(RP) (165). The 26S proteasome is activated by the binding of a 19S complex to each
end of the 20S cylinder (Figure 23). While 19S RP governs access of substrates to the
core, 20S CP contains proteolytic active sites accounting for substrate degradation
(165). The active sites of the CP are very sensitive to the 26S proteasome inhibitors,
such as MG115, MG132 and lactacystin (165, 166).
To get degraded by a 26S proteasome, first, a poly-ubiquitinated protein is
recognized by and bound to specific subunits in the 19S RP through its poly-Ub
chain(s). Next, the poly-Ub chains are removed by DUB(s) residing on the 19S RP.
After this, the substrate gets unfolded by ATPases also residing in the base of the 19S
RP. Then the unfolded polypeptide is inserted into the proteolytic chamber via an open
gate in the 20S CP in an ATP-dependent manner. In the lumen of the CP, the unfolded
polypeptides are broken down by the proteases (Figure 23) (166).

70

Figure 23. Structure of the 26S proteasome and the degradation process of a
poly-ubiquitinated protein.

(a) Structure of the 26S proteasome. The 26S proteasome is comprised of two
subcomplexes - the 20S CP, and the 19S RP. The 19S RP is composed of 17 core
subunits that are divided into the lid and base subcomplexes. The 20S is a cylindrical
stack of four heptameric rings, the two peripheral rings (α subunits) and the two central
rings (β subunits). Adapted with permission from Nat Rev Mol Cell Biol, Weissman,
Shabek, and Ciechanover, copyright 2011 (165)
(b) Diagram of the 26S proteasome combined with the predicted activities during the
degradation of a poly-ubiquitinated protein. Briefly, the 19S RP assists in recognizing
and unfolding the target, removing the Ubs, opening the gate of 20S CP, and then
directing the unfolded polypeptide into the lumen of the 20S CP for breakdown.
Adapted with permission from Trends Plant Sci, Vierstra, copyright 2003 (166)
Abbreviations: ATP, adenosine triphosphate; CP, catalytic particle; RP, regulatory
particle.
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PROTEOLYSIS: FROM THE LYSOSOME TO THE UBIQUITIN- PROTEASOME DEGRADATION

1. The brief history of the lysosome and the UPS

Even though the UPS is the most studied and common pathway in protein
degradation, lysosome was the first mechanism implicated in controlling protein
turnover (167).
Lysosome was discovered in early 1953 followed by an important discovery of
micro-autophagy, the basic functional mechanism of the lysosome. For a long time, the
lysosomal proteolytic pathway was thought to be “bulk” or non-specific degradation.
Long after, several findings indicated that lysosomal degradation could be specific and
was mediated by the recognition of a conserved and well-defined motif in target
proteins (KFERQ motif). The process of recognizing the specific substrates was later
known as the CMA (167).
The UPS was not discovered until late 1970s when some studies showed that
specific and general inhibitors of lysosomal proteases have different effects on different
populations of proteins (such as long-lived and short-lived proteins) (167). From this
finding, it was suggested that there were different proteolytic machineries function in
the cell. Through various studies on cell-free proteolytic system, the three enzymes that
are involved in the UPS were finally purified by Ciechanover and colleagues, which
were E1, E2 and E3, as described above (167-170). After that, another important
advance in the discovery of the UPS was done by Hough and colleagues, who partially
purified and characterized an alkaline protease that degraded ubiquitin conjugates of
lysozyme, but not untagged lysozyme, in an ATP-dependent manner (167, 171). This
72

protease finding, which later became known as the 26S proteasome, is the stepping
stone in the completion of the known UPS nowadays (167).

2. The intergration of the UPS and the (selective) lysosomal pathway

The UPS and the lysosomal proteolytic pathways are completely distinct in the
ways they functions. However, they both go through 4 common steps, including: (1)
target selection and recognition, (2) delivery of the target to the proteolytic machinery,
(3) target degradation in the proteolytic core and (4) recycling of constituent amino
acids (143).
There are several factors contributing to how a protein is recognized, such as
the half-life of a protein or the types of Ub linkages. However, the precise mechanism is
not completely understood (143). As mentioned above, one of the most well-studied
factors for determining the “fate” of a protein is whether the protein is attached via a
chain of Ub linked at K48 or K63 (K48 or K63-linked polyUb, respectively). While K48linked polyUb directs proteins to 26S proteasomes for destruction, proteins tagged with
K63-linked chains are targeted for lysosomal degradation (Figure 21) (143, 158, 162).
The relative contribution of each degradation pathway varies between cell types.
In

the

cells

cultured

under

stress-free

conditions,

proteasomal degradation

predominates (accounts for about 80% of intracellular protein degradation) (172).
However, in muscle cells, lysosomal pathways (specifically macro-autophagy) can
account for up to 40% of degradation of proteins (143, 172). Moreover, the proteasome
is itself degraded by starvation-induced macro-autophagy (173).
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Several studies showed that some cancer cells up-regulated either CMA or
macro-autophagy in response to the chemical blockage of the proteasome (144, 174,
175). It was reasoned that the induction in macro-autophagy or CMA may serve as an
alternative mechanism to protect the cells against toxicity of accumulated aggregate
proteins (144). Yet in what conditions CMA or macro-autophagy is activated is not
clear.
Interestingly, compromised CMA impairs the function of the UPS (176). The
mechanism is unknown, though it was suggested that CMA affected the turnover of
some of specific proteasome subunits leading to altering proteasome assembly (144,
173). Similarly, macro-autophagy deficiency also suppresses proteasome function
indicated by the increase in proteasomal substrates (Figure 24) (177).
In addition, CMA was also found to cross-talk with macro-autophagy during
starvation (176). When CMA is stimulated, macro-autophagy is first induced and then
inhibited (154, 176). Conversely, CMA is constitutively active in cells deficient in macroautophagy, yet little is known about the molecular modulators of all these crosstalks
(Figure 24) (178).
In conclusion, the UPS, the macro-autophagy and the CMA are strictly
connected to each other. Understanding the molecular determinants that efficiently
reroute a protein substrate from one proteolytic pathway to another would allow us to
better manipulate the various proteolytic systems and apply it to anti-cancer therapy.
For comprehensive reviews and experts’ opinions on the integration of the UPS and
lysosomal proteolytic pathway, please refer to articles by Wong and Cuervo (143, 144).
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Figure 24. Crosstalk between different proteolytic systems.

Different proteolytic systems are wired through multi-levels of interactions to maintain
cellular homeostasis. The inhibition or activation in one system could leads to the
elevation in the others to prevent toxicity to the cells.
Abbreviations: PD, Parkinson's disease; HD, Huntington's disease; SMA, spinal
muscular atrophy.
Adapted with permission from Cell Res, Cuervo and Wong, copyright 2014 (144)
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HYPOTHESIS AND SPECIFIC AIMS

Over-expression or an increase in the copy number of Jab1 is frequently found
in various cancers, contributing to tumor progression and drug resistance. In breast
cancer, Jab1 is over-expressed in 50% of primary cancers and 90% of metastatic
tumors, while its expression is low or absent in normal adult breast tissues.
Mechanistically, Jab1 promotes cell cycle progression and cell survival by facilitating
the rapid degradation of p27. Moreover, our group has shown that, in xenograft mouse
models refractory to trastuzumab, silencing Jab1 up-regulates both p27 and PTEN
protein levels in response to trastuzumab compared to control Jab1 knockdown. Downregulation of p27 or PTEN has been implicated in promoting trastuzumab resistance in
HER2+ breast cancer. However, the significance of Jab1 in mediating PTEN
expression and the cells’ responses to trastuzumab is unknown. The goal of my
dissertation is to understand the role of Jab1 in regulating PTEN expression and
trastuzumab resistance in HER2+ breast cancer. My central hypothesis is that Jab1
negatively regulates PTEN expression and promotes resistance to trastuzumab in
HER2+ breast cancer.

The specific aims of my dissertation project illustrated in Figure 25 are:
1. To identify the role of Jab1 in regulating PTEN expression and function (Chapter 3).
2. To elucidate the mechanism by which Jab1 suppresses PTEN expression (Chapter
4).
3. To characterize the role of Jab1 in conferring trastuzumab resistance (Chapter 5).
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Figure 25. Proposed hypothesis model of Jab1 role in regulating PTEN
expression and trastuzumab resistance in HER2-positive breast cancer.

Red lines indicate the inhibition; green lines indicate the activation; and black lines
represent unknown effects.
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CHAPER 2: MATERIALS AND METHODS

Cell culture

The human embryonic kidney 293T cells, the HER2+ human breast cancer cell lines BT474
and SKBR3 were obtained from ATCC. BT474 cells were cultured in Dulbecco’s modified
Eagle medium (DMEM), and SKBR3 was maintained in Roswell Park Memorial Institute
1640 medium (RPMI 1640). Trastuzumab-resistant C5 and C6 cells, which were derived
from BT474 cells and kindly provided by Dr. Timothy Kute (Wake Forest University,
Winston-Salem, NC), were maintained in DMEM with 2 g/ml of trastuzumab (179). Paired
MEF WT and MEF-Atg5 KO cells were kindly provided by Dr. Jiyong Liang (MD Anderson
Cancer Center, Houston, TX). Paired MEF-p62 WT and MEF-p62 KO were generously
given by Dr. Maria Diaz-Meco (Sanford-Burnham Medical Research Institute, La Jolla, CA)
(180). All the MEF cells were cultured in DMEM supplemented with 5% fetal bovine serum
(FBS). The other media used in this study were supplemented with 10% FBS, penicillin (100
U/ml), and streptomycin (100 μg/ml). All the cells were incubated at 37°C in a humidified
chamber supplemented with 5% CO2.

Cell proliferation MTS assay

Cell viability was assessed using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Promega). Cells were seeded for 24 hours
before the indicated treatments. After 5 days, the cell proliferation was assessed by adding
the MTS solution into each well. Wells with cell-free media were used as negative controls.
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The plates were incubated for the indicated times at 37°C in a humidified 5% CO 2
atmosphere. The color developed was read with an enzyme-linked immunosorbent assay
reader at 490 nm. The percentage of cell growth inhibition was calculated by comparing the
growth inhibition of the treated cells with that of the untreated cells. The results are the mean
values ± standard deviations.

Reagents and antibodies

Trastuzumab was kindly provided by Genentech/Roche. The proteasome inhibitors MG-132
and lactacystin were purchased from Calbiochem. The calpain inhibitor, pepstatin A, and
bafilomycin A were from Sigma-Aldrich. E64D was obtained from Santa Cruz. The anti-Jab1,
anti-p27, and anti-Myc antibodies were from Santa Cruz Biotechnology, BD Biosciences,
and Roche, respectively. Antibodies against p-PTEN (S380/T382/T383), p-Src (Y416), pAKT (S473), total Src, total AKT and ATG5 were from Cell Signaling Technology. The antip62 antibody was from PROGEN Biotechnik. Antibodies against LC3 and Hsc70 were
purchased from Novus Biologicals. Anti-β-actin and anti-Flag antibodies were from SigmaAldrich.

Western blot

Total cell lysates was prepared using lysis buffer supplemented with phosphatase inhibitors
and complete protease inhibitor tablet (Roche). The lysates were then separated by SDSPAGE, transferred to PVDF membrane (GE Healthcare) and blocked with 5% nonfat milk in
PBS with 0.1% Tween-20 (PBST). Membranes were incubated with primary antibodies
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overnight at 4˚C then washed with PBST. Secondary antibody was incubated with
membrane for 1-2 hour(s) at room temperature. Immunoreactive bands were detected with
horseradish peroxidase–conjugated secondary antibodies using the Western Lightning
Chemiluminescence Reagent (Thermo Scientific). β-Actin was used as the loading control
for all blots.

Small interfering RNA transfection

Small interfering (si) RNA against Jab1 (siJab1) was purchased from Ambion/Life
Technologies while siPTEN and siHsc70 were from Dharmacon. The Pepmute siRNA
transfection reagent (SignaGen) was used according to the manufacturer’s instructions to
deliver the siRNA into cells. 48 or 72 hours after transfection, the cells were collected for
Western blotting or real-time polymerase chain reaction (RT-PCR).

Generating shRNA stable cells from C5 and C6

JAB1 shRNA and luciferase (Luc) shRNA oligonucleotides as a control were cloned into a
retrovirus pSIREN-RetroQ system (Clontech) according to the manufacturer’s instructions.
The packaging cell line 293T was co-transfected with the helper vectors pCGP, pVSVG
vectors together with either Jab1-shRNA vector DNA or Luc-shRNA vector DNA using the
Lipofectamine PLUS reagent (Invitrogen). At 48 hours after transfection, the supernatant
was collected and filtered through 0.45-µm syringe filters, supplemented with Polybrene to a
final concentration of 8 µg/ml, and used to transduce the C5 and C6 cells for 16 hours. After
incubation, the medium was replaced with DMEM with 10% FBS. Stable clones were
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selected following treatment with puromycin at 1.0 µg/ml for 2 weeks. Positive clones were
further confirmed by western blot analysis, and clones were maintained in 0.4 µg/mL
puromycin.

PTEN lipid phosphatase assay

PTEN lipid phosphatase activity was assessed by its ability to de-phosphorylate PIP3 to
release free phosphate groups using Echelon’s Malachite Green Phosphatase Assay kits
(Echelon Bioscience). Briefly, cells were lysed in phosphatase inhibitor–free lysis buffer
according to the manufacturer’s protocol. PTEN proteins were immunoprecipitated from
lysates with anti-PTEN antibodies overnight following several thorough washes in reaction
buffer. The substrate, PIP3, was then added into the complexes, which were incubated at
37°C. The reaction without immunoprecipitated complexes was performed in parallel as the
negative control. After 1 hour, the reaction supernatants were transferred to a 96-well plate
and incubated with Malachite Green Solution at room temperature. The color developed was
measured at 650 nm using an enzyme-linked immunosorbent assay microplate reader. The
amount (in pmol) of free phosphate group released during each reaction was determined by
linear regression analysis against a standard phosphate curve.

Immunohistochemistry

The p-SRC-Y416 expression was assessed by immunohistochemical analysis on formalinfixed and paraffin-embedded tumors from mice injected with C5shLuc or C5shJab1 lines.
The monoclonal antibody used was specific for p-SRC-Y416 (diluted 1:50; Cell Signaling).
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Briefly, heat-induced retrieval of p-SRC-Y416 antigen was conducted, and the slides were
incubated with the primary antibody overnight. An immunoreaction was detected with the
LSAB+kit from DakoCytomation. We used 3,3′-diaminobenzidine as the chromogen and
hematoxylin as the counterstain. Tumor cells were considered positive for p-SRC-Y416
when

cytoplasmic

staining

was

present,

regardless

of

the

intensity.

The

immunohistochemistry results were evaluated by a pathologist in our lab. This study protocol
was approved by the institutional review board of MD Anderson Cancer Center

qRT-PCR

Total RNA was extracted using the Trizol total RNA isolation reagent (Invitrogen) according
to the manufacturer’s instructions. The RT-PCR assay was performed with 2 μg of total RNA
using the TaqMan mRNA assay kit (Life Sciences/Life Technologies), and the expression
levels of the mature mRNA were measured using the same kit following the manufacturer’s
protocol. A reaction without reverse transcriptase was performed in parallel to ensure the
absence of genomic DNA contamination. PTEN Primers used were designed and purchased
from Life Technologies (Assay ID: Hs02621230_s1).

Plasmid constructs and transfection

Jab1 (334 amino acid) was amplified by PCR, and the cDNA coding for full-length (1334) was cloned with an N-terminal Myc tag in the pcDNA3.1 vector (Invitrogen) to
generate pcDNA3.1-WT-Myc-Jab1. The N- and C- terminal deletion mutants ending at
codons 48, 93, and 299 (Jab1ΔN, Jab1ΔJBD, and Jab1ΔC, respectively) were
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produced by inserting stop codons at the mentioned positions, which generated the,
pcDNA3.1-Myc-Jab1ΔN, pcDNA3.1-Myc-Jab1ΔJBD, and the pcDNA3.1-Myc-Jab1ΔC.
pcDNA3.1-Myc-Jab1ΔMPN was generated by deleting amino acids from 138-151 of
WT Jab1. Site directed mutagenesis was performed using the QuikChange Lightning
Site- Directed mutagenesis kit (Stratagene). The entire ORF of all constructs and
mutations were checked by DNA sequencing (Beckman Coulter Genomics).
The plasmids pCMV-Flag-PTEN and pCMV-Flag-PTEN-3A were generously provided
by Dr. Maria-Magdalena Georgescu (The University of Texas Southwestern Medical
Center, Dallas, TX) (88).
Lipofectamine 2000 (Invitrogen) was used according to the manufacturer’s instructions
for the transfection of plasmid DNA into the cells. 48 or 72 hours after transfection, the
cells were subjected for different treatment or collected for further analysis by Western
blotting.

Immunoprecipitation

Cell lysates was prepared using lysis buffer supplemented with phosphatase inhibitors and
complete protease inhibitor tablet (Roche). Five hundred micrograms of cell lysate were
incubated with appropriate antibodies overnight at 4°C. Prewashed protein A/G agarose
beads (Upstate) were then added into Ab-lysate mixers and rotated for 2-4 h at 4°C. The
beads were washed three times with lysis buffer and centrifuged for 10 min at 5,000 × g.
Proteins were eluted from the beads with 20 μl of loading buffer and subjected to Western
blotting as described above.
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Nuclear and cytoplasmic fractionation

Fractionations of the cells were performed using an NE-PER nuclear and cytoplasmic
extraction reagent kit (Thermo Scientific/Pierce) according the manufacturer’s specifications.

Cycloheximide (CHX) study

293T cells stably expressing Flag-tagged wild-type PTEN (WT PTEN) or Flag-tagged mutant
PTEN-3A (PTEN-3A) were incubated with cycloheximide (CHX) (50 g/ml) and harvested at
the indicated times. Whole protein lysates were extracted and subjected to Western blotting
with an anti-FLAG antibody for transfected PTEN; anti–β-actin antibody was used as the
loading control.

In vivo ubiquitination assay

293T cells were co-transfected with control vectors and/or plasmids encoding Flag-PTEN,
Myc-Jab1, and His-tagged WT ubiquitin (His-Ub-WT) or His-tag mutated Ub from lysine to
arginine at site 48 or 63 (K48R or K63R). His-Ub-WT and mutated isoforms were generously
given by Dr. Shiaw-Yih Lin (MD Anderson Cancer Center, Houston, TX). Part of the lysates
were used for western blot analsys. The rest of the lysates were subjected to
immunoprecipitation in which the expressed His-tag Ub proteins were immunoprecipitated
using Nickel beads against His-tag. Subsequently, Western blott against the Flag tag was
performed to detect ubiquitinated PTEN.
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Bioinformatic and statistical analysis

Gene and protein expression data from the TCGA Breast Invasive Carcinoma (BRCA)
(n=744) were downloaded from cbioPortal (181, 182) (http://www.cbioportal.org/publicportal/). The samples were grouped by mRNA expression levels of COPS5 (Jab1 gene),
WWP2, or NEDD4. Expression levels of the given genes were defined as High (≥ upper
quartile) and Low (≤ lower quartile).
Protein expression data were downloaded from the TCPA BRCA (n=750) (183)
(http://app1.bioinformatics.mdanderson.org/tcpa/_design/basic/index.html).

The

samples

were grouped by protein expression levels of Jab1 measured by reverse phase protein array
(RPPA), in which protein levels were defined as High (≥ upper quartile) and Low (≤ lower
quartile). For the two datasets, PTEN protein levels, measured by RPPA, were analyzed for
each group and represented by box-and-whisker plots. The p-value was calculated using the
Mann–Whitney test. P values <0.05 were considered statistically significant.
For the in vitro and in vivo analysis, experiments were repeated at least three times. The
data were presented as means ± standard deviations. Statistical calculations were
performed with Microsoft Excel analysis tools. Differences between individual groups were
analyzed using a t test. P values <0.05 were considered statistically significant.
Quantification of protein levels was done using ImageJ software from the National Institutes
of Health (http://rsb.info.nih.gov/ij).
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CHAPTER 3: THE ROLE OF JAB1 IN REGULATING PTEN EXPRESSION AND
FUNCTION IN HER2-POSITIVE BREAST CANCER

RATIONALE

One of the mechanisms contributing to trastuzumab resistance in HER2+ breast
cancer is the reduced expression of PTEN protein levels, which results in constitutive
active AKT. However, it is not fully understood how PTEN protein is down-regulated in
breast cancer despite the lack of PTEN gene mutation or promoter methylation (98,
99). Therefore, it is critical to understand the mechanism driving PTEN protein low
expression and to effectively restore PTEN level in HER2+ breast cancer. Our group
previously showed that in xenograft mouse models refractory to trastuzumab, silencing
of Jab1 together with trastuzumab treatment up-regulated PTEN protein level, which
was not observed in control Jab1 knockdown mice (unpublished data). However, the
functional correlation between Jab1 and PTEN was not understood. In this chapter, my
goal is to examine whether the inhibition of Jab1 alone is sufficient to restore PTEN
protein expression and function in HER2+ breast cancer.

RESULTS

1. Jab1 silencing but not trastuzumab treatment restores PTEN protein expression in
HER2-positive breast cancer cell lines resistant to trastuzumab
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1.1. Trastuzumab treatment does not affect the proliferation and downstream
signaling of HER2 in HER2-positive breast cancer cells that were made resistant
to this drug

I first evaluated trastuzumab inhibitory effects on the growth of a HER2+ breast
cancer cell line, BT474 and two BT474-derived trastuzumab-resistant lines, C5/BT474
(i.e., C5) and C6/BT474 (i.e., C6). As presented in Figure 26A (left graph), trastuzumab
inhibited the proliferation of BT474 (blue line), but had no effects on C5 and C6 cells
(red and green lines). IgG does not affect the growth of any of these cell lines (Figure
26A, right graph). Also, I demonstrated that HER2 protein levels were relatively similar
among the three lines, BT474, C5 and C6 (Figure 26B). The unchanged in HER2
protein indicates that the responses of the cells to trastuzumab treatment are
dependent on HER2 downstream alterations rather than the levels of HER2 per se.
Next, I identified the effects of trastuzumab on downstream signaling targets of
HER2 in BT474, C5 and C6 cells which are PTEN and AKT phosphorylation at serine
473 (p-AKT-S473). I treated theses cells with either IgG or increasing concentrations of
trastuzumab and examined the changes in protein levels by western blot. As mentioned
in chapter 1, the key mechanism by which trastuzumab inhibited cancer cell
proliferation was to increase PTEN protein expression and decrease p-AKT-S473
(table 2). Consistently, I showed that in trastuzumab-responsive BT474 cells, increased
treatment with this drug enhanced PTEN level accompanied by the decrease in p-AKTS473 level (Figure 27A). In contrast, trastuzumab did not alter PTEN or p-AKT-S473
levels in C5 and C6 cells (Figure 27B).
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These data, together, confirm that trastuzumab shows no effect on either cell
proliferation or downstream signaling of HER2 in trastuzumab resistant cells.
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Figure 26. Effects of trastuzumab on HER2-positive breast cancer cells that are
sensitive or resistant to trastuzumab.

(A) Growth rates of BT474, C5 and C6 lines treated with trastuzumab (left graph) or
with control IgG (right graph) were measured by MTS assay. Experiments were
repeated three times. The data were presented as means ± standard deviations.
Differences between individual groups were analyzed using a t test. P values <0.05
were considered statistically significant, which were represented by the asterisk (*).
(B) Western blot showing protein expressions of HER2 protein in BT474, C5 and C6
lines.
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Figure 27. Effects of trastuzumab on the downstream signaling of HER2 in HER2positive breast cancer cells that are sensitive or resistant to trastuzumab.

Western blot showing changes in PTEN and p-AKT-S473 levels in (A) BT474 and (B)
C5 and C6 lines treated with control IgG or increasing concentrations of trastuzumab.
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1.2. Inhibition of Jab1 up-regulates PTEN protein expression in HER2-positive
breast cancer cells resistant to trastuzumab

To evaluate the effect of Jab1 on PTEN protein levels, I first transiently depleted
Jab1 using small interfering (si) RNA in BT474, C5 and C6 cells. I found that in
trastuzumab sensitive BT474 cells, transient silencing of Jab1 slightly increased PTEN
protein while decreased p-AKT-S473 without affecting total AKT (T-AKT) levels (Figure
28). In trastuzumab resistant C5 and C6 cells, Jab1 knockdown showed stronger effect
on up-regulating PTEN, compared to this effect observed on BT474 cells (Figure 28).
To confirm the finding that depletion of Jab1 increased PTEN protein level in
trastuzumab resistant cells, I generated stable Jab1 knockdown cells in C5 and C6
cells called C5shJab1 and C6shJab1. C5shLuc and C6shLuc, in which the luciferase
gene was depleted, were used as the control knockdown cells. As presented in Figure
29A, the levels of PTEN protein were increased by more than 2-fold as a result of
stable inhibition of Jab1 in the C5shJab1 and C6shJab1 cells, compared to the shLuc
cells. Consistently, p-AKT-S473 levels were markedly decreased in C5shJab1 and
C6shJab1 cells, compared to C5shLuc and C6shLuc cells (Figure 29A). Quantitative
data from repeated experiments confirmed my finding that suppression of Jab1 leads to
the increase in PTEN protein expression in trastuzumab resistant cells (Figure 29B).
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Figure 28. Transient depletion of Jab1 increases PTEN and decreases p-AKTS473 levels in trastuzumab-sensitive and trastuzumab-resistant cells.

Western blot representing the changes in protein expressions of Jab1, PTEN, p-AKTS473 and T-AKT in BT474, C5 and C6 cells transfected with mock oligonucleotide
(siCtrl) or siRNA against Jab1 (siJab1) for 72 h.
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Figure 29. Stable knockdown of Jab1 increases PTEN and decreases p-AKT-S473
levels in trastuzumab-resistant cells.

(A) Western Blot analysis of indicated proteins in C5shLuc and C5shJab1, or C6shLuc
and C6shJab1.
(B) Bar graph shows the relative fold changes in PTEN proteins between C5shLuc and
C5shJab1, or C6shLuc and C6shJab1. The relative fold change represents the protein
expression value of PTEN in cells bearing shJab1 normalized to the expression value
of PTEN in cells bearing control shLuc.
Experiments were repeated three times. The data were presented as means ±
standard deviations. Differences between individual groups were analyzed using a t
test. P values <0.05 were considered statistically significant.
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2. Jab1 is inversely correlated with PTEN protein expression in patients with invasive
breast cancer

Next, to identify if Jab1 was also clinically associated with PTEN, I analyzed the
correlation between Jab1 mRNA and PTEN protein expressions using The Cancer
Genome Atlas (TCGA) Breast Invasive Carcinoma (BRCA) dataset. The correlation
between Jab1 protein and PTEN protein expressions was also analyzed using The
Cancer Protein Atlas (TCPA) BRCA dataset. I found that in both the TCGA and TCPA
BRCA datasets, higher PTEN protein levels were associated with lower Jab1 mRNA or
protein levels. Similarly, PTEN protein expressions were lower in the group with high
expressions of Jab1 mRNA or protein (Figure 30). I also noticed that Jab1 protein
(Figure 30B) showed much stronger association with PTEN protein expression than
Jab1 mRNA did (Figure 30A). In general, this negative correlation between Jab1 and
PTEN are consistent with my experimental findings that silencing Jab1 resulted in
elevation in PTEN protein expressions in breast cancer.
As discussed in chapter 1, previous work of other groups showed that PTEN
protein expressions were negatively regulated by E3 ligases which are NEDD4-1 and
WWP2 (91, 92, 94). Therefore, I compared the degree of clinical correlation between
Jab1 and PTEN with these two proteins and PTEN using the TCGA BRCA data, since
protein expressions for WWP2 and NEDD4 were not available for TCPA BRCA. In
contrast to prior experimental data, WWP2 mRNA and PTEN protein are not clinically
correlated while NEDD4-1 mRNA shows positive correlation with PTEN protein
expression in human breast tumors (Figure 31A and B, respectively).

94

In general, my findings strongly argue that high expression of Jab1 is causally
linked to low expression of PTEN in human breast cancers.
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Figure 30. Jab1 amplification is correlated with low PTEN protein expression in
clinical specimens of invasive breast carcinoma.

Differences in protein levels of PTEN between High and Low groups of (A) Jab1 mRNA
or (B) Jab1 protein expressions in TCGA BRCA (n=744) and TCPA BRCA (n=750)
datasets, respectively. In box-and-whisker plots, horizontal bold bars indicate the
medians, boxes indicate 25th to 75th percentiles, and whiskers indicate minimum and
maximum values. P value was calculated by Mann–Whitney U test. P values <0.05
were considered statistically significant.
Data analysis was performed by Tyler Moss, MD Anderson Cancer Center, Houston,
TX.
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Figure 31. The correlation of PTEN protein with mRNA levels of other regulators
of PTEN.

Box-and-whisker plots representing differences in protein levels of PTEN between (A)
WWP2-High and WWP2-Low and (B) NEDD4-High and NEDD4-Low cases in TCGA
BRCA dataset (n=744). P value was calculated by Mann–Whitney U test. P values
<0.05 were considered statistically significant.
Data analysis was performed by Tyler Moss, MD Anderson Cancer Center, Houston,
TX.
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3. Inhibition of Jab1 stabilizes PTEN which results in increases in lipid and tyrosine
phosphatase functions

PTEN is well-known for its phosphatase function (86). Therefore, I next
examined whether the increases in PTEN protein levels due to depletion of Jab1 also
led to the increase in the lipid and tyrosine phosphatase functions of PTEN. As the
effects of Jab1 on altering PTEN protein expression were more significant in the two
trastuzumab-resistant C5 and C6 cells compared to trastuzumab-sensitive BT474 cells
(Figure 26), I used the C5 and C6 cells to examine how Jab1 regulated PTEN activities.

3.1. Jab1 negatively regulates PTEN lipid phosphatase activity

I first tested the impact of silencing Jab1 on PTEN lipid phosphatase activity by
measuring the ability of PTEN to de-phosphorylate PIP3 using Malachite Green
Phosphatase Assay. As shown in Figure 32, the lipid phosphatase activity was two-fold
higher in shJab1-bearing C5 and C6 cells than in control shLuc-bearing C5 and C6
cells. The data indicate that inhibition of Jab1 enhances PTEN lipid phosphatase
activity.
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Figure 32. Depletion of Jab1 enhances PTEN ability to de-phosphorylate PIP3.

Bar graph indicating differences in free phosphate group released during PTEN
phosphatase reactions in C5 and C6 cells stably transfected with shLuc or shJab1. The
changes in free phosphate relatively reflect the changes in PTEN lipid phosphatase
activity between these cells.
Experiments were repeated three times. The data were presented as means ±
standard deviations. Differences between individual groups were analyzed using a t
test. P values <0.05 were considered statistically significant.
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3.2. Jab1 negatively regulates PTEN tyrosine phosphatase activity

In addition to its lipid phosphatase activity, PTEN was reported to specifically dephosphorylate p-Src at Y416 (84). Therefore, I tested whether the depletion of Jab1
also altered p-Src-Y-416 levels in C5 and C6 cells. As shown in Figure 33A, stable
silencing of Jab1 decreased p-Src-Y416 levels in these cells, which was confirmed by
quantitative data from repeated experiments (Figure 33B).
Next, I examined whether depletion of Jab1 also affected p-Src-Y416 levels in
paraffin-embedded tumors from mice injected with C5shLuc or C5shJab1 lines. The
immunohistochemical analysis demonstrated that knockdown of Jab1 in C5 tumor
xenografts significantly decreased p-Src-Y416 compared to control Luc knockdown
(Figure 34). This result implied the increase in PTEN tyrosine phosphatase activity due
to inhibition of Jab1 in xenograft mice.
Together, these data indicate that silencing Jab1 results in increased PTEN
tyrosine phosphatase function in breast cancer.
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Figure 33. Knockdown of Jab1 enhances PTEN ability to de-phosphorylate p-SrcY416 in HER2-positive breast cancer cells.

(A) Western Blot analysis of indicated proteins in C5shLuc and C5shJab1, or C6shLuc
and C6shJab1.
(B) Bar graph shows the relative fold changes in p-Src-Y416 proteins between
C5shLuc and C5shJab1, or C6shLuc and C6shJab1. The relative fold change
represents the protein expression value of p-Src-Y416 in cells bearing shJab1
normalized to the expression value of p-Src-Y416 in cells bearing shLuc. Experiments
were repeated three times. The data were presented as means ± standard deviations.
Differences between individual groups were analyzed using a t test. P values <0.05
were considered statistically significant.
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Figure 34. Knockdown of Jab1 decreases p-Src-Y416 in mouse xenografts.

(A) and (B) p-Src-Y416 expressions in paraffin-embedded tumors of mice injected with
C5shLuc or C5shJab1 lines.
(A) Immunohistochemical staining of p-Src-Y416. Tumor cells were considered positive
for p-Src-Y416 when cytoplasmic staining was present (brown cells). Scale bar,
100μm. Immunohistochemical staining was performed by Ronghua Zhang, MD
Anderson Cancer Center, Houston, TX.
(B) Graph representing the positive scores of p-Src-Y416 expression in the cytoplasm.
The scoring was performed by Sumei Wang, MD Anderson Cancer Center, Houston,
TX (n=3 tumor slides per group).
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3.3. Knockdown of Jab1 decreases p-Src-Y416 in a PTEN-dependent manner

Next, I investigated if Jab1 per se was able to mediate the level of p-Src-Y416
without PTEN expression. To address this question, I depleted Jab1 in MDA-MB-468, a
PTEN-deficient breast cancer cells to examine how this affected p-Src-Y416 level. As
presented in Figure 35, silencing of Jab1 did not alter p-Src-Y416 expression in MDAMB-468 cells.
Next, I silenced PTEN using siRNA in stable Jab1 knockdown cells, C5shJab1
and C6shJab1. C5shLuc and C6shLuc were used as paired controls for Jab1
knockdown. I noticed that in C5 cells with normal PTEN expression (siCtrl), silencing of
Jab1 consistently decreased the expression of p-Src-Y16 about 50% (Figure 36A).
However, once PTEN was inhibited by siPTEN, inhibition of Jab1 did not show any
effect on p-Src-Y416 level (Figure 36A). Similar results were observed for the pair of
C6shLuc and C6shJab1 (Figure 36B).
In conclusion, these data suggest that Jab1 alters p-Src-Y416 expression in a
PTEN-dependent manner.

103

Figure 35. Depletion of Jab1 in PTEN-deficient breast cancer cells shows no
effect on p-Src-Y416 level.

Western blot showing protein expressions of Jab1, PTEN, p-Src-Y416 and T-Src in
MDA-MB-468 cells transfected with siCtrl or siJab1 for 72 h.
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Figure 36. The loss of PTEN impairs the effect of Jab1 on altering p-Src-Y416
expression level.

(Top) Western Blot analysis of Jab1, PTEN, p-Src-Y416 and T-Src in (A)
C5shLuc/C5shJab1 and (B) C6shLuc/C6shJab1 cells that were transiently transfected
with siCtrl or siPTEN.
(Bottom) Densitometry of relative fold changes in protein levels of p-Src-Y416 in (A)
C5shLuc/C5shJab1 and (B) C6shLuc/C6shJab1 cells that were transiently transfected
with siCtrl or siPTEN.
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CONCLUSION

My studies in this chapter demonstrate that depletion of Jab1 is sufficient to
stabilize PTEN protein in HER2+ breast cancer cells.
Specifically, I found that silencing Jab1 affected PTEN more significantly in
trastuzumab resistant cells (C5 and C6) compared to trastuzumab-sensitive cells
(BT474). Based on the protein expression of Jab1 in BT474, C5 and C6 cells (Figure
28), I hypothesized that Jab1 level was higher in C5 and C6 cells which implied that
depletion of Jab1 would create more significant effect on these cells than on BT474
cells. This hypothesis was further examined in chapter 5.
In addition, my studies showed that Jab1 expression was negatively correlated
with PTEN protein expression in human breast invasive carcinoma specimens (Figure
30). Breast tumors with high Jab1 tend to have low PTEN while tumors with low Jab1
tend to have high expression of PTEN. I also observed that there was a stronger
correlation between Jab1 protein and PTEN protein than between Jab1 mRNA and
PTEN protein. There are two possible reasons for this difference: (1) TCGA BRCA may
contain the mutated Jab1 gene which may not be correlated with PTEN expression and
(2) the amplification of Jab1 gene does not always reflect the over-expression of Jab1
protein.
Moreover, I demonstrated that elevation in PTEN protein level due to depletion
of Jab1 was accompanied by the increases in PTEN tyrosine and lipid phosphatase
functions (Figures 32-35). As mentioned in chapter 1, PTEN converts PIP3 to PIP2
which results in decreased p-AKT-S473 level and increased free phosphor group (82,
83, 184). Consistently, in this chapter, I demonstrated that the increase in PTEN level
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due to Jab1 knockdown was corroborated with the increase in PTEN ability to dephosphorylate PIP3 and p-AKT-S473 (Figures 28, 29, and 32). In addition, I
demonstrated that Jab1 knockdown, by enhancing PTEN protein expression, resulted
in decreased p-Src-416 level (Figures 33-35) which indicated the increase in PTEN
tyrosine phosphatase activity (84). In general, I identified that the negative effects of
Jab1 on phosphatase function of PTEN were consistent with the major effect of Jab1 in
negatively decreasing PTEN protein levels.
In conclusion, all these results together suggest that inhibition of Jab1 stabilizes
PTEN protein which subsequently leads to increased PTEN lipid and tyrosine
phosphatase functions. The molecular mechanisms of Jab1 that governs PTEN
expression will be the focus of Chapter 4.
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CHAPTER 4: THE MOLECULAR MECHANISMS BY WHICH JAB1 SUPPRESSES
PTEN EXPRESSION

RATIONALE

The activity of PTEN can be regulated at many levels, including transcriptional
regulation, posttranslational modifications (phosphorylation and ubiquitination) or
through protein-protein interaction (86). Studies in Chapter 3 demonstrated that Jab1
negatively regulated PTEN in HER2+ breast cancer cell lines. The goal of the studies in
this chapter is to elucidate the mechanism of Jab1 that mediates PTEN expression.

RESULTS

1. Jab1 mediates the posttranslational regulation of PTEN expression

1.1. Jab1 physically associates with PTEN protein

First, I investigated whether Jab1 regulated PTEN at a transcriptional level. I
performed quantitative real-time PCR (qRT-PCR) to analyze the effect of Jab1
depletion on PTEN mRNA levels in BT474 and C5 cells. I found that neither transient
nor stable knockdown of Jab1 significantly affected PTEN mRNA levels in BT474 or C5
cells (Figure 37A and B). This suggests that Jab1 may mediate post-transcriptional
regulation of PTEN.
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I next investigated whether PTEN associated with Jab1 by immunoprecipitation
(IP). For endogenous interaction analysis, lysates of a HER2+ breast cancer cell line
SKBR3 were immunoprecipitated with an anti-Jab1 or anti-PTEN antibody and then
subjected to Western blotting with anti-PTEN and anti-Jab1 antibodies. SKBR3 cells
immunoprecipitated with IgG antibody were used as controls. As presented in Figure
38A, endogenous PTEN was pulled down by Jab1 antibody and endogenous Jab1 was
immunoprecipitated with PTEN antibody in SKBR3 line. For exogenous interaction
analysis, I transfected 293T cells with Flag-tagged PTEN (Flag-PTEN) and Myc-tagged
Jab1 (Myc-Jab1) then performed the IP. I showed that exogenous Flag-PTEN and MycJab1 cross co-immunoprecipitated in 293T cells (Figure 38B).
These results together strongly suggest that Jab1 and PTEN proteins physically
interact.
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Figure 37. Silencing of Jab1 does not affect PTEN mRNA expression.

(A) (top) Western blot and (bottom) qRT-PCR analyses of PTEN expressions in BT474
cells transiently transfected with siCtrl or increasing concentrations of siJab1.
(B) (top) Western blot and (bottom) qRT-PCR analyses of PTEN expressions in
C5shLuc and C5shJab1 cells. Experiments were repeated three times. The data were
presented as means ± standard deviations.
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Figure 38. Jab1 and PTEN proteins cross co-immunoprecipitate.

Co-immunoprecipitation analysis of (A) endogenous and (B) exogenous Jab1 and
PTEN in SKBR3 and 293T cells, respectively.
Minus signs (-) indicates empty vector transfection.
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1.2. C-terminal end of Jab1 is required for Jab1 to regulate PTEN expression

Next, I identified the domain of Jab1 that was required for its association with
PTEN. I used plasmids bearing wild-type (WT) Jab1 or a series of Jab1 deleting
mutants that were previously generated in my lab (109). These mutants were deleted at
the N-terminal (Jab1ΔN), the C-terminal (Jab1ΔC), the c-Jun binding domain
(Jab1ΔJBD), or the MPN domain (Jab1ΔMPN) of Jab1 (Figure 39A).
Each of these mutants was co-transfected with Flag-PTEN followed by IP in
293T cells. The 293T cells transfected with empty vector or WT Jab1 alone were used
as controls. Consistent with my previously presented data, Jab1 and PTEN associated
(Figure 39B, lane 4). I further demonstrated that, compared to WT Jab1, the mutants
Jab1ΔMPN, Jab1ΔN, and Jab1ΔJBD, had more than 3-fold increase in their abilities to
immunoprecipitate PTEN (Figure 39B, lanes 4, 6, 7, and 8). In contrast, Jab1ΔC had a
decreased ability to immunoprepitate PTEN of approximately 2-fold compared to WT
Jab1 (Figure 39B, lanes 4 and 5).
Next, to verify that the C-terminal end of Jab1 is required for Jab1 to associate
with PTEN, I over-expressed increasing amounts of WT Myc-Jab1 (WT Jab1) or MycJab1ΔC (Jab1ΔC) into BT474 and SKBR3 cells and compared their effects on
endogenous PTEN levels. Consistent with the IP data, while over-expression of WT
Jab1 decreased endogenous PTEN protein expressions in a dose-dependent manner,
Jab1ΔC showed no effect on PTEN level in BT474 and SKBR3 cells (Figure 40A and
B, respectively). Similar findings were observed when I co-transfected Flag-PTEN with
increasing amounts of either WT Jab1 or Jab1ΔC in 293T cells. Jab1 WT gradually
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degraded exogenous Flag-PTEN while Jab1ΔC lost the ability to degrade exogenous
Flag-PTEN (Figure 41).
To rule out the possibility that the differences in the association of these
isoforms with PTEN was affected by their protein expression or subcellular localization,
I transfected each of these constructs alone into 293T cells and examined their protein
levels and their localizations. I found that all Jab1 WT and mutant constructs expressed
similar protein levels and exhibited a cytoplasmic localization in 293T cells (Figure 42A
and B, respectively).
Taken all together, my findings indicate that Jab1 regulates PTEN through
protein-protein interaction and that this function requires the intact C-terminal end of
Jab1.
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Figure 39. Wild-type and mutants of Jab1 show different abilities to
immunoprecipitate PTEN.

(A) Schematic representation of WT Jab1 and its deleting mutants.
(B) Immunoprecipitation analysis of exogenous Flag-PTEN with exogenous WT MycJab1 (WT Jab1) or different mutants of Myc-Jab1.
Minus signs (-) indicates empty vector transfection.
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Figure 40. Deletion of the C-terminal end of Jab1 impairs its ability to degrade
endogenous PTEN in HER2-positive breast cancer cells.

Western Blots showing the changes in expression levels of endogenous PTEN in (A)
BT474 and (B) SKBR3 transfected with increasing amounts of WT Jab1 (left panel) or
Jab1ΔC (right panel).
Minus signs (-) indicates empty vector transfection.
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Figure 41. Deletion of the C-terminal end of Jab1 abolishes its ability to degrade
exogenous PTEN.

Western Blots showing the changes in expression levels of exogenous Flag-PTEN in
293T cells co-transfected with increasing amounts of WT Jab1 (left panel) or Jab1ΔC
(right panel).
Minus signs (-) indicates empty vector transfection.
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Figure 42. Exogenous wild-type Jab1 and different mutants of Jab1 show similar
level of protein expression and exhibit cytoplasmic localization.

(A) Western Blot representing total protein expressions of WT Jab1 and its mutants in
293T cells.
(B) Nuclear-cytoplasmic fractionations of transfected WT Jab1 or different mutants of
Jab1 in 293T cells.
Minus signs (-) indicates empty vector transfection.
Abbreviations: C: cytoplasmic fraction; N: nuclear fraction.
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2. Jab1 interacts with phosphorylated and de-phosphorylated PTEN

PTEN is frequently down-regulated in breast cancer, and PTEN mutations
contribute to its low expression in tumors (86, 87). Herein, I examined if PTEN
mutations affected the association with Jab1. Structurally, PTEN consists of a PIP3binding domain, a phosphatase domain, a C2 domain, and a C-terminal tail with a PDZ
binding motif (Figure 43A) (86). As mentioned in chapter 1, the C-terminal tail of PTEN,
specifically the phosphorylation clusters of S380/T382/T383, mediated PTEN stability
and its interactions with other proteins (87, 90). Therefore, I focused my study on this
cluster region of PTEN (Figure 43A, red lines). First, I compared the interaction of Jab1
with WT PTEN and of Jab1 with the phosphorylation-defective PTEN-3A. The PTEN3A is a mutant in which the three phosphorylation sites, S380, T382 and T383 of PTEN
were mutated to un-phosphorylatable alanine residues (Figure 43B). I co-transfected
the 293T cells with Myc-Jab1 and either Flag- WT PTEN (WT PTEN) or Flag-PTEN-3A
(PTEN-3A). The 293T cells transfected with empty vector or Flag-PTEN alone were
used as controls. Using the co-IP, I demonstrated that PTEN-3A bound Jab1 more
efficiently than WT PTEN did (Figure 43C, lanes 5 and 4).
To examine whether the increased binding of PTEN-3A to Jab1 led to its faster
degradation by Jab1, I transfected 293T cells with either WT PTEN or PTEN-3A in the
presence or absence of Jab1. As compared to WT PTEN, the introduction of Jab1
completely degraded PTEN-3A (Figure 44A, lanes 2 and 4). I then compared the
degradation kinetics of WT PTEN with PTEN-3A. I transfected WT PTEN or PTEN-3A
with or without Jab1 into 293T cells followed by short-term blockade of translation with
cycloheximide (CHX). The protein expressions of WT PTEN or PTEN-3A in the
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presence or absence of Jab1 at different time points were measured using Image J and
were blotted in Figure 44B. I showed that compared to WT PTEN alone (blue line), the
turnover of WT PTEN was much faster in presence of Jab1 (red line), which is
consistent with my previous data. In addition, I demonstrated that the half-life of PTEN3A (Figure 44, green line) was shorter compared to the half-life of WT PTEN (Figure
44, blue line). I further showed that in the presence of Jab1, PTEN-3A (Figure 44, pink
line) was degraded about 4 times faster compared to PTEN-3A alone (Figure 44, green
line).
Taken together, these findings suggest that Jab1 facilitates the degradation of
both WT PTEN and PTEN-3A.
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Figure 43. De-phosphorylation of PTEN at the clusters of Serine380 and
Threonine382/383 increases PTEN binding to Jab1.

(A) Schematic representation of WT PTEN and its phosphorylation-defective PTEN-3A
mutant (the three un-phosphorylatable alanine residues S380A, T382A and T383A
were marked by red lines).
(B) Western blot showing the expressions of exogenous p-PTEN (S380/T382/T383)
and (total) PTEN in 293T cells transfected with Flag-WT PTEN or Flag-PTEN-3A.
(C) Immunoprecipitation analysis of Myc-Jab1 with Flag-WT PTEN or Flag-PTEN-3A.
Minus signs (-) indicates empty vector transfection.
All experiments were performed in 293T cells.
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Figure 44. In the presence of Jab1, mutant PTEN-3A is degraded faster by Jab1
compared to wild-type PTEN.

(A) Western Blot showing changes in protein expressions of exogenous WT PTEN or
PTEN-3A, in the presence or absent of Jab1.
(B) Line graph representing the degradation kinetics of WT PTEN or PTEN-3A with or
without Jab1.
Minus signs (-) indicates empty vector transfection.
All experiments were performed in 293T cells.
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3. Jab1 does not regulate PTEN protein expression through the UPS in HER2-positive
breast cancer

3.1. Proteasome inhibitors increase PTEN poly-ubiquitination but do not prevent
PTEN degradation mediated by Jab1

I have shown that Jab1 mediated post-translational regulation of PTEN, which
decreased PTEN protein stability and subsequently PTEN phosphatase activity. I next
elucidated the mechanism by which Jab1 controlled PTEN protein expression. As
mentioned in chapter 1, the majority (~80%) of intracellular proteins were reported to
go through the UPS for degradation, including PTEN (86, 87). To address whether
Jab1 also facilitated PTEN degradation through the UPS, I first tested if PTEN stability
is mediated through the UPS pathway. I transfected the 293T cells with Flag-PTEN and
treated the cells with either DMSO as a control or MG-132, a potent inhibitor of 26S
proteasome. The changes in ubiquitination pattern of exogenous PTEN between the
two treatment groups were then examined. Consistent with previous work (92, 94, 95), I
observed a robust increase in PTEN poly-ubiquitin (poly-Ub) pattern with the addition of
MG-132 compared with DMSO treatment (Figure 45).
Next, to determine if blocking proteasome activity restored PTEN expression in
the presence of Jab1, the BT474 cells were transfected with increasing amount of MycJab1 and then were treated with either DMSO or MG-132. I found

that

similar

to

DMSO treatment, MG-132 failed to prevent PTEN degradation due to over-expression
of Jab1 in BT474 cells (Figure 46). To verify the results, I transfected BT474 cells with
the same amount of Myc-Jab1 and treated the cells with either DMSO or different
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proteasome inhibitors (MG-132, LLnL, and Lactacystin). Figure 47A showed that
compared to DMSO treatment, these inhibitors prevented p27 destruction when Jab1
was over-expressed, which is consistent with prior work of others. This restoration in
p27 protein expression also indicates that the proteasomal activity was blocked by
these inhibitors. In contrast, treatment with these inhibitors did not prevent PTEN
degradation induced by over-expression of Jab1 (Figure 47A). Quantitative data from
repeated experiments confirmed my findings that these proteasome inhibitors failed to
prevent PTEN degradation in the presence of Jab1 (Figure 47B). These results
together imply that Jab1 does not facilitate PTEN degradation through the 26S
proteasome pathway.
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Figure 45. MG-132 treatment results in the accumulation of PTEN polyubiquitination.

In vivo ubiquitination analysis of exogenous PTEN poly-ubiquitination patterns in 293T
cells treated with DMSO or MG132.
Abbreviations: His-Ub, His-tagged ubiquitin; IB, immunoblot (western blot); IP,
immunoprecipitation. Minus signs (-) indicates DMSO treatment or empty vector
transfection.
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Figure 46. Over-expression of Jab1 facilitates PTEN degradation in BT474 cells
treated with either DMSO or MG-132.

Western blot showing protein expressions of endogenous PTEN in BT474 cells
transfected with increasing amounts of Myc-Jab1 and then treated with DMSO or MG132.
Minus signs (-) indicates empty vector transfection.
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Figure 47. Proteasome inhibitors do not prevent PTEN degradation induced by
over-expression of Jab1.

(A) Western blot showing protein expressions of endogenous PTEN, and p27 in BT474
cells transfected with empty vector or the same amount of Myc-Jab1 and then treated
with DMSO or different proteasome inhibitors.
(B) Graph representing the means of PTEN protein expression levels from repeated
experiments as described in (A). Experiments were repeated three times. The data
were presented as means ± standard deviations. Differences between individual
groups were analyzed using a t test. P values <0.05 were considered statistically
significant.
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3.2. In the presence of Jab1, proteasome inhibitors fail to accumulate PTEN polyubiquitination

If a protein is degraded through the UPS, the addition of a proteasome inhibitor
will lead to the increase in protein expression and the accumulation in protein poly-Ub
(166). I identified that though proteasome inhibitors resulted in the accumulation of
PTEN poly-Ub, the treatment failed to prevent PTEN degradation induced by Jab1.
Therefore, I next evaluated the effects of proteasome inhibitors on PTEN poly-Ub in the
presence of Jab1. I co-transfected the 293T cells with the same amounts of FlagPTEN, His-tagged ubiquitin (His-Ub) and increasing amount of Myc-Jab1. 293T cells
transfected with either Flag-PTEN or His-Ub alone were used as controls. After treating
the cells with MG-132 to block the 26S proteasome activity, I performed the in vivo
ubiquitination assay to examine the changes in the ubiquitination pattern of PTEN. As
presented in Figure 48, lanes 1, 2 and 3, PTEN was ubiquitinated in the presence of
His-Ub. However, I found that even with the addition of MG-132, over-expression of
Jab1 markedly decreased PTEN ubiquitination (Figure 48, lanes 3, 4, 5, and 6).
As discussed in chapter 1, Jab1 contains the MPN domain, which was thought
to de-ubiquitinase ubiquitinated proteins (Figure 39A) (110, 112, 118). Therefore, to
rule out the possibility that Jab1 facilitated the de-ubiquitination of PTEN, I overexpressed the Jab1 mutant lacking the MPN domain (Jab1ΔMPN) into 293T cells and
examined the changes in PTEN ubiquitination. Similarly, PTEN ubiquitination was
decreased by the over-expression of Jab1ΔMPN, even in the presence of MG-132
(Figure 48, lanes 7, 8, and 9). In addition, I noticed that PTEN was ubiquitinated less
effectively in the presence of Jab1ΔMPN than in the presence of WT Jab1 (Figure 48,
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lanes 4 and 7). These data suggests that the decreases in PTEN ubiquitination are not
mediated by the potential de-ubiquitinase activity of Jab1.
Together, these findings strongly argue that the UPS is not the major
mechanism underlying the effect of Jab1 on PTEN stability.
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Figure 48. Over-expression of either wild-type Jab1 or mutant Jab1ΔMPN
reduces PTEN poly-ubiquitination.

In vivo ubiquitination analysis of Flag-PTEN poly-ubiquitination in 293T cells
transfected with increasing amounts of WT Myc Jab1 or Jab1ΔMPN and treated with
MG132.
Minus signs (-) indicates empty vector transfection.
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4. Jab1 mediates PTEN degradation through the lysosomal pathway in HER2-positive
breast cancer

4.1. Inhibition of lysosomal enzymes impairs Jab1 ability to degrade PTEN

As mentioned in chapter 1, the UPS pathway usually mediated the degradation
of proteins attached to K48-Ub chains; the lysosomal proteolytic pathway regulates
substrates modified by K63-linked polyUb (143). To determine whether the polyUb
chain of PTEN was linked at K48 or at K63, I co-transfected Flag-PTEN with either UbWT, K48R-mutant ubiquitin (Ub-K48R), or K63R-mutant ubiquitin (Ub-K63R) in 293T
cells and performed in vivo ubiquitination assays. The controls were 293T cells
transfected with either Ub-WT or Flag-PTEN alone. The K48R- or K63R-mutant in
which the K (lysine) was mutated to the R (arginine) lost the ability to form the polyubiquitin chains. I found that mutation at K48 of Ub did not significantly affect the
ubiquitination pattern of PTEN compared to WT Ub (Figure 49, lanes 5 and 3). Instead,
I noticed that mutation at K63 of Ub markedly reduced PTEN poly-ubiquitination
compared with Ub-WT or Ub-K48R (Figure 49, lanes 4, 3 and 5). These results implied
that PTEN poly-Ub chain was predominantly linked at K63. Therefore, I hypothesized
that Jab1 mediated PTEN degradation mainly through the lysosomal system.
To address this hypothesis, I first examined the effect of the lysosomal enzyme
inhibitors- E64D and pepstatin A- on PTEN protein expression in BT474 cells
transfected with increasing amounts of myc-Jab1. I found that this combined treatment
led to an increase in the conversion of LC3-I to LC3-II accompanied by an
accumulation of p62 compared with DMSO-treated cells (Figure 50A). As discussed in
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chapter 1 (table 3), the increase in LC3 and p62 indicated impaired lysosomal function
(185). Similar to my previous findings, in the control DMSO treatment, increases in
Jab1 led to gradual decreases in PTEN (Figure 50A, left panel). However, in the E64D
and pepstatin A treatment, PTEN was not degraded by over-expression of Jab1 (Figure
50A, right panel). Quantitative data from repeated experiments confirmed that
lysosomal inhibitors completely restored PTEN expression, even when Jab1 was overexpressed (Figure 50B).
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Figure 49. Mutation of ubiquitin at lysine 63 reduces PTEN poly-ubiquitination
compared to wild-type ubiquitin or mutation of ubiquitin at lysine 48.

In vivo ubiquitination analysis of PTEN poly-ubiquitination in 293T cells co-transfected
with Flag-PTEN and either Ub-WT, Ub-K48R, or Ub-K6R, then treated with MG132.
Minus signs (-) indicates empty vector transfection.
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Figure 50. Inhibitors of lysosomal enzymes prevent PTEN degradation induced
by over-expression of Jab1.

(A) Western blot showing protein expressions of autophagy markers (p62 and LC3)
and PTEN in BT474 cells transfected with increasing amounts of Myc-Jab1 and then
treated with DMSO or lysosomal enzyme inhibitors E64D and pepstatin A.
(B) Bar graph representing the means of PTEN protein expression levels from repeated
experiments as described in (A). Experiments were repeated three times. The data
were presented as means ± standard deviations. Differences between individual
groups were analyzed using a t test. P values <0.05 were considered statistically
significant.
Minus signs (-) indicates empty vector transfection.
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4.2. PTEN degradation-mediated by Jab1 does not occur through the macroautophagy pathway

As discussed in chapter 1, in mammalian cells, there are three distinct pathways
that deliver proteins for lysosomal degradation: macro-autophagy, chaperone-mediated
autophagy (CMA), and micro-autophagy (143). Among these mechanisms, macroautophagy is the best-characterized pathway and has been found to directly mediate
the degradation of poly-ubiquitinated-proteins through their association with p62. I first
investigated whether macro-autophagy delivered PTEN for lysosomal degradation. I
treated the BT474 cells with a macro-autophagy inhibitor bafilomycin A (142). I
observed that p62 protein was accumulated while LC3-II was not formed in bafilomycin
A–treated cells compared with DMSO-treated cells (Figure 51), which indicates that
macro-autophagy flux is defective (table 3). However, bafilomycin A had minimal effect
on PTEN levels (Figure 51).
Next, I compared the effect of Jab1 on PTEN in paired MEF WT cells and the
MEF cells lacking an essential macro-autophagy-related gene ATG5 (MEF-ATG5 KO).
I found that p62 protein was accumulated while LC3-II was not formed in MEF-ATG5
KO cells compared with MEF WT cells (Figure 52A), which is consistent with the
previous work of others (table 3). My western blot and quantitative analysis shown in
Figure 52A and B indicated that PTEN was gradually degraded due to the overexpression of Jab1 in both MEF WT and MEF-ATG5 KO cells.
In conclusion, these data demonstrate that neither pharmacologic inhibition of
macro-autophagy nor genetic removal of a critical macro-autophagy gene prevents
degradation of PTEN induced by over-expressing Jab1.
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Since direct inhibition of macro-autophagy did not rescue PTEN expression, I
investigated whether p62 was required for Jab1-mediated PTEN degradation. I
compared the effects of over-expressing Jab1 on PTEN in MEF-p62 WT and MEF-p62
KO cells. I found that depletion of p62 also failed to prevent degradation of PTEN
mediated by Jab1 over-expression (Figure 53A and B). Taken all data together, I
conclude that although Jab1 requires functional lysosomes to degrade PTEN, this
degradation does not occur through the macro-autophagy pathway.
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Figure 51. Bafilomycin A has minimal effects on PTEN protein expression levels.

Western blot showing the changes in protein expression levels of ATG5, autophagy
markers (p62 and LC3-II), and PTEN in BT474 treated with DMSO (0) or increasing
concentrations of bafilomycin A.
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Figure 52. Jab1 facilitates PTEN degradation in MEF WT and MEF-ATG5 KO.

(A) Western blot showing protein expressions of ATG5, autophagy markers (p62 and
LC3) and PTEN in MEF WT and MEF-ATG5 KO transfected with increasing amounts of
Myc-Jab1.
(B) Bar graph representing the means of PTEN protein expression levels from repeated
experiments as described in (A). Experiments were repeated three times. The data
were presented as means ± standard deviations. Differences between individual
groups were analyzed using a t test. P values <0.05 were considered statistically
significant.
Minus signs (-) indicate empty vector transfection.
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Figure 53. Jab1 facilitates PTEN degradation in MEF-p62 WT and MEF-p62 KO.

(A) Western blot showing protein expressions of autophagy markers (p62 and LC3)
and PTEN in MEF-p62 WT and MEF-p62 KO cells transfected with increasing amounts
of Myc-Jab1.
(B) Graph representing the means of PTEN protein expression levels from repeated
experiments as described in (A). Experiments were repeated three times. The data
were presented as means ± standard deviations. Differences between individual
groups were analyzed using a t test. P values <0.05 were considered statistically
significant.
Minus signs (-) indicate empty vector transfection.
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4.3. PTEN stability is regulated through the CMA pathway

I then assessed the contribution of the CMA pathway in regulating PTEN
degradation. The first step in the CMA pathway is the recognition of CMA substrates by
Hsc70 through the KFERQ-like motifs in the substrates (table 4) (146). Using a
screening program developed by a computational biologist at MD Anderson Cancer
Center, I found that PTEN contained a KFERQ-like motif (330KDKAN334) in the C2domain (Figure 54, top). The alignment of PTEN sequences of different species around
this KDKAN motif was then generated using the Clustal Omega web server. As shown
in Figure 54, bottom, the KDKAN motif was conserved across species, which suggests
that this motif plays a critical role in PTEN function during evolution.
Furthermore,

structural

analysis

using

PyMOL

program

revealed

that

330KDKAN334 motif is located on the surface of human PTEN and is solvent
accessible, suggesting that this motif on PTEN is accessible by Hsc70 (Figure 55A and
B).
Next, I examined the effects of silencing Hsc70 on PTEN protein expression. I
found that LC3 level was not affected by Hsc70 silencing which implied that lysosomal
function was not impaired. On the other hand, I showed that depletion of Hsc70 in
BT474 cells led to an approximately 90% increase in PTEN protein levels (Figure 56).
Taken together, my results provide preliminary finding that PTEN stability is regulated
specifically through the CMA pathway in breast cancer cells.
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Figure 54. The KDKAN motif is located in the C2 domain of PTEN and is
evolutionarily conserved.

(Top) Schematic representing PTEN structure.
(Bottom) Sequence alignment around the KDKAN motif (highlighted with light brown)
in PTEN collected from six species. All PTEN sequences were obtained from the
Uniprot database. The alignment was generated using the Clustal Omega web server.
Identification and alignment of the KDKAN motif were performed by Lu Chen, MD
Anderson Cancer Center, Houston, TX.
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Figure 55. The KDKAN motif locates on the surface of PTEN protein and is
solvent accessible.

(Left) The 3D structure of human PTEN (protein data bank identifier 1D5R) built by
PyMOL. The KDKAN motif in the C2 domain of PTEN was represented with sticks and
mesh.
(Right) Close-up of the KDKAN motif interface in human PTEN.
The structure of PTEN was generated by Lu Chen, MD Anderson Cancer Center,
Houston, TX.
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Figure 56. Depletion of Hsc70 increases PTEN protein expression level.

Western blot showing changes in PTEN protein levels in BT474 cells transfected with
either siCtrl or increasing amounts of siHsc70.
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CONCLUSION

The studies in this chapter provide significant insight into the molecular
mechanism by which Jab1 regulates PTEN expression in breast cancer cells.
Firstly, I demonstrated that Jab1 did not affect PTEN mRNA expression (Figure
37). Instead, Jab1 bound to PTEN and facilitated PTEN protein degradation (Figures
38 and 39). Secondly, I found that deletion of the C-terminal end of Jab1 abolished the
ability of Jab1 to degrade PTEN while deletion of the other domains (MPN, N-terminal,
and JBD domains) increased Jab1 abilities to associate with PTEN (Figures 39-41). I
further demonstrated that the changes in their associations with PTEN were
independent of their sub-cellular localization and/or protein expressions (Figure 42).
Further, I showed that compared to WT PTEN, the de-phosphorylated PTEN at
the cluster of S380/T382/T383 (PTEN-3A) was degraded faster and preferentially
associated with Jab1 (Figures 43 and 44). Several studies have identified that this
phosphorylation cluster regulates PTEN conformational changes and PTEN stability. In
another words, PTEN-3A is in the “open” conformation and less stable than “closed”
WT PTEN (78, 80). Therefore, I propose a model in which PTEN is de-phosphorylated
at this cluster and exposes its C-tail, which makes it more accessible for Jab1 to
associate with and facilitating PTEN degradation (Figure 57).
Furthermore, I showed that blocking the 26S proteasome resulted in the
accumulation of PTEN poly-ubiquitination (Figure 45), which is consistent with previous
studies (92, 94, 95). However, I found that in the presence of Jab1, proteasome
inhibitors did not prevent the degradation or the reduction in poly-ubiquitination of
PTEN (Figures 46-48). Importantly, I demonstrated that PTEN poly-ubiquitination was
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predominantly linked at K63 chains rather than at K48 chains (Figure 49). As
mentioned in chapter 1, while proteins tagged with K48-linked poly-ubiquitin were target
for proteasomal degradation, proteins with K63-linked chain were not recognized by
proteasome system but are degraded by the lysosomal proteolytic pathway (143, 158).
Consistence with these studies, I showed that inhibition of lysosomal activity but not
proteasomal activity prevented PTEN destruction due to over-expression of Jab1 in
breast cancer cells (Figure 50). Using chemical blockage and genetic inhibition of
macro-autophagy, I demonstrated that macro-autophagy did not play a dominant role in
translocating PTEN to the lysosome for degradation (Figures 51-53). Rather, I provided
preliminary data that CMA regulated PTEN degradation (Figures 54-56).
Taking all these results together, I conclude that Jab1 interacts with PTEN
protein and facilitates PTEN degradation through the lysosomal proteolytic pathway
(Figure 57).
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Figure 57. Proposed model in which the de-phosphorylation of PTEN at
Serine380/Threonine382/383 leads to the degradation of PTEN by Jab1.
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CHAPTER

5:

THE

ROLE

OF

JAB1

IN

CONFERRING

TRASTUZUMAB

RESISTANCE IN HER2-POSITIVE BREAST CANCER

RATIONALE

The loss of PTEN and the rapid degradation of p27 are the two key mechanisms
proposed to contribute to the resistance to trastuzumab (62). As mentioned in chapter
1, over-expression of Jab1 accelerated p27 degradation in breast cancer (114). In
Chapters 3 and 4, I demonstrated that Jab1 was negatively correlated with PTEN in
HER2+ breast cancer cells and in breast tumor specimens. Specifically, I showed that
up-regulation of Jab1 facilitated PTEN degradation while depletion of Jab1 restored
PTEN levels in HER2+ breast cancer lines. Therefore, the goal of the studies in this
chapter is to determine the role of Jab1 in trastuzumab resistance in HER2+ breast
cancer.

RESULTS

1. Jab1 protein is up-regulated in HER2-positive breast cancer lines that are resistant
to trastuzumab

To understand the role of Jab1 in responses of HER2+ breast cancer cells to
trastuzumab, I first compared the level of Jab1 protein expression in trastuzumabresponsive and trastuzumab-resistant cells. I found that protein levels of Jab1 was
lower in trastuzumab-sensitive BT474 cells compared to C5 and C6 cells that were
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unresponsive to trastuzumab (Figure 58A). I also noticed that Jab1 protein was
significantly elevated in C5 cells compared to Jab1 levels in BT474 and C6 cells
(Figure 58A). The quantitative data from repeated experiments confirm my finding that
Jab1 is over-expressed in HER2+ breast cancer cells that are resistant to trastuzumab
(Figure 58B).
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Figure 58. Trastuzumab-resistant cells show higher protein expressions of Jab1
compared to trastuzumab-sensitive cells.

(A) Western blot comparing protein expressions of Jab1 in BT474, C5 and C6 lines.
(B) Graph representing the means of Jab1 protein levels from repeated experiments as
described in (A). Experiments were repeated three times. The data were presented as
means ± standard deviations. Differences between individual groups were analyzed
using a t test. P values <0.05 were considered statistically significant.
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2. Alterations in expression levels of Jab1 mediate the responses of HER2-positive
breast cancer cells to trastuzumab

2.1. Over-expression of Jab1 confers breast cancer cells resistance to
trastuzumab

I showed that over-expression of Jab1 down-regulated PTEN and that Jab1 was
up-regulated in HER2+ breast cancer cells unresponsive to trastuzumab. Next, I
identified the effects of Jab1 over-expression on the responses of HER2+ breast
cancer cells to trastuzumab treatment. I introduced exogenous Myc-Jab1 into BT747
cells then treated the cells with either trastuzumab or IgG. The BT474 cells transfected
with empty vector was used as controls. The expression of Myc-Jab1 was confirmed by
western blot. After 5 days of incubation, the cell proliferation was measured using MTS
assay. As shown in Figure 59A, though the Myc-Jab1 protein levels were decreased by
days, expression of Myc-Jab1 was able to be detected at the day of 5 of the
experiment. Further, I showed that over-expression of Jab1 reduced cells’ responses to
trastuzumab about 10% compared with the responses of the control BT474 cells
(Figure 59B, left graph). IgG showed similar non-inhibitory effects on both control
BT474 cells and Myc-Jab1 transfected cells (Figure 59B, right graph). Together, these
findings indicate that Jab1 over-expression confers BT474 cells resistance to
trastuzumab.
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Figure 59. Over-expression of Jab1 antagonizes trastuzumab inhibitory effects in
BT474 cells.

(A) Western blot showing protein levels of Myc-Jab1 in BT474 for different days.
(B) Growth rates of BT474 cells transfected with either empty vector or Myc-Jab1 and
treated with increasing concentrations of trastuzumab (left graph) or control IgG (right
graph). Experiments were repeated three times. The data were presented as means ±
standard deviations. Differences between individual groups were analyzed using a t
test. P values <0.05 were considered statistically significant, which were represented
by the asterisk (*).
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2.2. Silencing Jab1 increases trastuzumab inhibitory effect

If activation of PTEN and p27 are the keys to the therapeutic action of
trastuzumab and if inhibition of Jab1 significantly restores PTEN and p27 levels, cancer
cells that have lost Jab1 should be more responsive to this drug. To test this
hypothesis, I treated the stable Jab1 knockdown C5 and C6 cells with either
trastuzumab or IgG. The C5shLuc and C6shLuc lines were used as controls. The
expression of Jab1 was confirmed by western blot. After 5 days, the cell proliferation
was measured using MTS assay. I showed that the protein expressions of Jab1 were
barely detected in C5shJab1 and C6shJab1 compared to C5shLuc and C6shLuc,
respectively (Figure 60A). As shown in Figure 60B, the left graph, at the concentration
of 100 g/ml, trastuzumab started to have inhibitory effect on the proliferation of
C5shJab1 and C6shJab1 (red and purple lines, respectively) but not C5shLuc and
C6shLuc (blue and green lines). IgG did not show any effects on any of the four cell
lines (Figure 60B, right graph). These results suggest that depletion of Jab1 increases
the sensitivities to trastuzumab treatment in HER2+ breast cancer cells.
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Figure 60. Depletion of Jab1 increases trastuzumab inhibitory effects in C5 and
C6 cells.

(A) Western blot showing expression levels of Jab1 protein in pairs C5shLuc/C5shJab1
and C6shLuc/C6shJab1 lines.
(B) Growth rates of C5shLuc/C5shJab1 and C6shLuc/C6shJab1 cells treated with
increasing concentrations of trastuzumab (left graph) or control IgG (right graph).
Experiments were repeated three times. The data were presented as means ±
standard deviations. Differences between individual groups were analyzed using a t
test. P values <0.05 were considered statistically significant, which were represented
by the asterisk (*).
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CONCLUSION

In this chapter, I elucidated the role of Jab1 in mediating responses of HER2+
breast cancer cells to trastuzumab.
I found that in the cells that were refractory to trastuzumab, Jab1 protein was
significantly up-regulated compared with the trastuzumab-responsive cells (Figure 58).
My studies also demonstrated that silencing Jab1 in these resistant cells enhanced
inhibitory effects of trastuzumab on the cell growth (Figure 60). Conversely, introducing
Jab1 into trastuzumab-sensitive cells conferred the cells resistance to this drug (Figure
59).
Together, my results indicate that Jab1 positively contributes to trastuzumab
resistance in HER2+ breast cancer cells.
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CHAPTER 6: DISCUSSION

My studies in chapter 3 demonstrated that in HER2+ breast cancer, silencing
Jab1 led to increase in PTEN protein expression and phosphatase function. My studies
further showed that high Jab1 expression was associated with low PTEN expression in
human breast tumor specimens. My subsequent studies in chapter 4 elucidated that
Jab1 mediated the post-translational regulation of PTEN through the lysosomal
proteolytic pathway. Consistent with the role of Jab1 in facilitating PTEN degradation
and reducing PTEN function, my studies in Chapter 5 demonstrated that silencing Jab1
sensitized trastuzumab-resistant cells to the drug. In constrast, over-expressing Jab1 in
trastuzumab-sensitive cells reduced the cells response to trastuzumab’s inhibitory
effects.

1. Jab1 negatively regulates protein expression of PTEN in HER2-positive breast
cancer

PTEN mutations and its role as a negative regulator of PI3K signaling have been
extensively studied (86). However, relatively little is known about the pathway(s)
controlling PTEN stability and activity. My studies in chapter 3 and chapter 4 expand on
this field by demonstrating that Jab1 negatively regulates PTEN stability, thus
modifying PTEN lipid and tyrosine phosphatase functions.
In chapter 3, I showed that silencing Jab1 up-regulated PTEN in HER2+ breast
cancer cells that were either sensitive or resistant to trastuzumab (Figures 26, 28, and
29). I also found that up-regulation of PTEN due to Jab1 silencing was more significant
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in trastuzumab-resistant cells compared to trastuzumab-sensitive cells (Figures 27 and
28). My studies in chapter 5 further clarified these differences by identifying that protein
levels of Jab1 were at least 2-fold higher in these resistant cells compared with the
sensitive cells (Figure 58). As the Jab1 protein is higher in the resistant cells, it is
expected that the silencing Jab1 would create more significant effects in these cells.
The finding that the degree of increased PTEN due to Jab1 knockdown depends on
Jab1 expression levels also suggest that targeting Jab1 is more beneficial in the cells
over-expressing Jab1 compared with the cells having low level of Jab1.
Two independent studies have shown that NEDD4-1 protein is negatively
correlated with PTEN protein and that NEDD4-1 degrades PTEN protein in non-small
cell lung cancer (91, 92). Later, Maddika and colleagues (2011) by using an unbiased
approach (tandem affinity-purification), demonstrated that WWP2 interacted with PTEN
and that over-expression of WWP2 facilitated PTEN degradation. However, this group
could not verify that inhibition of NEDD4-1 led to increased PTEN protein expression
(94). In my studies in chapter 3, the correlations of mRNA levels of WWP2 and
NEDD4-1 with PTEN protein in invasive breast carcinoma in the TCGA BRCA dataset
did not support that WWP2 and NEDD4-1 were negatively correlated with PTEN
protein expression. Instead, I showed that WWP2 mRNA and PTEN protein were not
clinically correlated whereas NEDD4-1 mRNA was positively correlated with PTEN
protein level in human breast tumors (Figure 31A and B, respectively). There are two
possible explanations: (1) PTEN degradation mediated by NEDD4-1 is cell-type
dependent and (2) mRNA expressions of NEDD4-1 and WWP2 do not correlated with
their protein expression levels. Given the protein expressions of NEDD4-1 and WWP2
are not available in TCPA BRCA dataset, further studies are needed to confirm the
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clinical correlation of these two proteins with PTEN levels. On the other hand, I
demonstrated that Jab1 mRNA was the only to show the negative correlation with
protein expression of PTEN in clinical specimens of invasive breast carcinoma (Figure
30A). I also showed that in TCPA BRCA dataset, PTEN protein levels were significantly
lower in the clinical specimens with high Jab1 protein expressions (Figure 30B). Taking
these findings together, my results strongly argue that high expression of Jab1 is
causally linked to low expression of PTEN in human breast carcinoma.
I further demonstrated that this elevation in PTEN protein due to Jab1
knockdown was accompanied by increases in the ability of PTEN to de-phosphorylate
PIP3 and p-Src-Y416 (Figures 32-34). This increase in PTEN phosphatase activity
suggests an increase in the amount of functional PTEN present in the cells. As
mentioned in chapter 1, PTEN protein down-regulation was common in breast cancer
and was associated with tumor progression and resistance to targeted therapies such
as trastuzumab (98, 99). Growing evidence also supports that subtle changes in the
dose of PTEN can have profound effects on tumor susceptibility (101, 102). My
findings, therefore, suggest a therapeutic implication for targeting Jab1 in order to
restore PTEN expression and function and thus, improve the effectiveness of breast
cancer therapies. My studies in chapter 5 provided preliminary evidence for the
therapeutic application of inhibiting Jab1 by demonstrating that depletion of Jab1
enhanced trastuzumab inhibitory effects in the cells resistant to this drug (Figures 58
and 60).
My studies in chapter 4 further showed that PTEN and Jab1 physically
interacted and that the C-terminal end of Jab1 was required for its association with
PTEN and for subsequent PTEN degradation (Figures 38-41). In contrast, deletion at
156

the MPN, N-terminal or JBD domains of Jab1 markedly increased interactions between
Jab1 and PTEN proteins (Figure 39). It was possible that different mutations resulted in
the changes in protein expression or subcellular localizations which may affect proteinprotein interaction. However, I showed that all WT and mutant Jab1 isoforms showed
similar protein levels and expressed in the cytoplasm. The results on one hand suggest
that the C-terminal end of Jab1 likely represents the docking region where PTEN
interacts with Jab1. On the other hand, the finding imply that the deletion at the MPN,
N-terminal or JBD domains leads to changes in Jab1 conformation which makes it
more accessible to PTEN.
Several studies have proposed that there was a steady-state switch between the
“open” and “closed” conformations of PTEN, which mediates protein-protein interaction
(78, 80, 88, 90). These groups also found that the phosphorylated PTEN at the Cterminal tail, specifically at S380, T382, and T383, was predominantly in a “closed”
conformation, which stabilized PTEN (Figure 13) (78, 80, 88). In contrast, the unphosphorylated PTEN (PTEN-3A) was predominantly in an “open” conformation and
less stable. Similarly, my studies in chapter 4 demonstrated that “closed” WT PTEN
was more stable than “open” PTEN-3A (Figure 43). Interestingly, I demonstrated that
Jab1 associated with both WT PTEN and PTEN-3A. Additionally, PTEN-3A showed
two-fold higher binding to Jab1 which resulted in faster degradation of PTEN-3A by
Jab1 compared to WT PTEN (Figures 43 and 44). I predicted that the
nonphosphorylated/ “open” conformation of PTEN makes it more accessible to Jab1,
resulting in the rapid degradation of PTEN by Jab1 (Figure 57). To verify the model,
future work is needed to compare the kinetics of PTEN and PTEN-3A in association
with Jab1.
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In conclusion, my studies in chapter 3 and chapter 4 demonstrate that Jab1
regulates PTEN stability and function through its interaction with PTEN

2. Jab1 facilitates PTEN degradation through the lysosomal proteolytic pathway

A number of models have proposed that the UPS controls PTEN stability (86).
Recently, four independent studies comprehensively showed that PTEN ubiquitination
was accumulated in the presence of proteasome inhibitors. These studies also
identified that addition of proteasome inhibitors restored PTEN protein expression (91,
92, 94, 95). My findings in chapter 4 showed that PTEN poly-ubiquitination was
markedly increased when 26S proteasome was inhibited by MG-132 (Figure 45), which
is consistent with these studies. However, I observed that in the presence of Jab1,
blocking 26S proteasomal activity failed to prevent the accumulation in PTEN polyubiquitination (Figure 48). Additionally, over-expressing Jab1 led to gradual decrease in
PTEN protein levels in breast cancer cells, even in the presence of proteasome
inhibitors (Figures 46 and 47). My findings supported that the stability of PTEN per se
was regulated by the UPS in a normal condition. However, in breast cancer cells with
over-expressed Jab1, there was an alternative mechanism that regulated PTEN protein
degradation.
In eukaryote cells, besides the UPS, proteins can be degraded through the
lysosomal proteolytic pathway (143). A well-studied signal for determining the pathway
that degrades a protein is through its poly-ubiquitin chains. Among them, K48- and
K63- linked chains have been reported to mediate protein degradation (155, 159).
Precisely, several groups have consistently showed that K48-linked poly-ubiquitin
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targets a protein for proteasomal degradation while K63-linked chains represent signal
for lysosomal degradation (160-162, 186). My studies in chapter 4 found that PTEN
poly-ubiquitination was predominantly linked at the K63 rather than the K48 (Figure 49).
This result implied that PTEN destruction was mediated through the lysosomal
pathway. My studies later validated this hypothesis by showing that blocking the activity
of lysosomal proteases impaired the ability of Jab1 to facilitate PTEN degradation. In
addition, when Jab1 was up-regulated, lysosomal inhibitors significantly increased
PTEN levels (Figure 50). These findings indicate that lysosomal inhibitors potentially
restore PTEN protein levels in breast cancer cells with high levels of Jab1.
In mammalian cells, there are three pathways that deliver a protein for lysosomal
degradation, macro-autophagy, CMA, and micro-autophagy (129, 143). Among them,
macro-autophagy and CMA have been experimentally reported to crosstalk with the
UPS to regulate protein degradation. In my studies in chapter 4, I showed that
pharmacological inhibition of macro-autophagy did not show any effect on PTEN
protein expression. Previous studies demonstrated that targeted manipulation of
macro-autophagy (such as ATG5 or p62 knockdown) impaired protein degradation
(130, 134). In my studies, I found that neither ATG5 nor p62 knockdown prevented
PTEN degradation induced by Jab1 over-expression (Figures 52 and 53). These
findings indicate that macro-autophagy does not play a critical role in the Jab1mediated PTEN degradation.
Instead, I identified that PTEN contained the KDKAN motif (Figure 54) which is a
recognition motif for CMA degradation (148). I also showed that this motif was solvent
accessible (Figure 55) which suggests that this motif can be recognized by the CMA
mediator. In the CMA process, Hsc70 was the only protein that can bind to the CMA
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recognition motif on a substrate and translocate it to the lysosome for destruction (150,
153). In my studies, I demonstrated that depletion of Hsc70 significantly up-regulated
PTEN protein expressions in breast cancer cells without affecting lysosomal function
(Figures 56).
Moreover, it was demonstrated that a reduction in macro-autophay could
promote CMA activity (178). My data previously suggested that inhibition of the CMA
rather than macro-autophagy was effective in restoring PTEN expression. My findings
therefore support that the activation of CMA due to inhibition of macro-autophagy
results in effective degradation of PTEN protein. As CMA is a comprehensive multiprocess and that 30% of cellular proteins contains the CMA motif (144, 147), further
studies are required to confirm that PTEN is a bona fide CMA substrate (table 4). Also,
whether Jab1 regulates PTEN expression through the CMA pathway is a critical
question to be address.
It was previously shown that proteasome inhibitors prevented PTEN degradation
in breast cancer cells and that there was crosstalk between the UPS, macroautophagy, and CMA (86, 144). My results in general demonstrated that in the
presence of Jab1, blocking the lysosome, but not proteasomal activity, prevented
PTEN degradation and that CMA rather than macro-autophagy may regulate PTEN
degradation. My unexpected findings raise important questions regarding the exact
pathway mediating PTEN degradation. For instance, in what contexts is PTEN
degraded through the UPS or through the CMA? One possible explanation for my
finding is that Jab1 over-expression together with proteasome or macro-autophagy
inhibitors triggers cellular stress, which activates maximal CMA activity and
subsequently leads to rapid degradation of PTEN. Therefore, it is also important to
160

clarify how Jab1 and CMA co-oporate to regulate PTEN stability and function in breast
cancer.
Taken together, my findings demonstrate that the lysosomal proteolytic pathway
is the dominant mechanism by which Jab1 controls PTEN stability in HER2+ breast
cancer. I speculate that selective inhibition of lysosomal enzymes in combination with
targeting the Jab1-PTEN binding domain would effectively restore PTEN levels which
are frequently reduced in breast cancer. This would subsequently decrease p-AKT and
p-Src levels and also increase responsiveness of breast cancers to targeted therapy
including trastuzumab.

3. Jab1 over-expression confers breast cancer cells resistance to trastuzumab

It is well-studied that the loss of PTEN and the constitutive active AKT and Src
play pivotal role in trastuzumab resistance (98, 99, 106). In chapter 3 and 4, I
demonstrated that over-expressing Jab1 led to significant reduction in PTEN protein
expression and increases in active AKT and Src. Also, I found that PTEN is required for
Jab1 to mediate p-Src levels. Other studies of our group showed that PTEN is also
required for Jab1 to mediate p-AKT levels (unpublished data). In my studies in Chapter
5, I showed that Jab1 protein was significantly up-regulated in the cells that were
refractory to trastuzumab compared with the trastuzumab-responsive cells (Figure 58).
In addition, over-expression of Jab1 was significantly correlated with the poor response
rate to trastuzumab (Figure 59). Consistently, I demonstrated that silencing Jab1 in
these resistant cells enhanced inhibitory effects of trastuzumab (Figure 60), which is
consistent with the functional effects of increased PTEN expression and function due to
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Jab1 depletion. These results imply that Jab1 confers trastuzumab resistance through
regulating PTEN expression and function. Yet further studies are needed to confirm the
effects of PTEN in trastuzumab resistance mediated by Jab1.
In general, my findings provide in vitro evidence that inhibition of Jab1 or of
Jab1-PTEN interaction could overcome resistance to trastuzumab. Moreover, I
speculate that the elevation of Jab1 together with the down-regulation of PTEN can
serve as predictive markers for the response to trastuzumab in HER2+ breast cancer
cells.

4. Conclusion and future directions

4.1. Conclusion

My studies support a model in which high expression of Jab1 in HER2+ breast
cancer antagonizes the inhibitory effects of trastuzumas and promotes PTEN
degradation through the lysosomal proteolytic pathway (Figure 61). PTEN downregulation mediated by Jab1 in turn increases p-Src-Y416 and p-AKT-S473 levels
which also contribute to the resistance to trastuzumab (Figure 61).
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Figure 61. Proposed model in which Jab1 negatively regulates PTEN protein and
confers resistance to trastuzumab in HER2-positive breast cancer.

Red lines indicate the inhibition and green lines indicate the activation.
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4.2. Future directions

 To demonstrate that Jab1 facilitates PTEN degradation through the CMA
pathway
My studies in chapter 4 indicated that PTEN contains the CMA-recognition motif
and that inhibition of a CMA mediator (Hsc70) prevented PTEN degradation in breast
cancer cells (Figures 55-57). As discussed in chapter 1 (table 4), to confirm that PTEN
is an authentic CMA substrate, the next steps are to identify (1) whether PTEN
physically interacts with Hsc70 and lysosomal membrane LAMP-2A and (2) whether
mutated PTEN at the KDKAN motif can still be recognized by Hsc70 or LAMP-2A.
Furthermore, if Jab1 mediates PTEN degradation via the CMA pathway,
selective inhibition of this pathway should block PTEN degradation induced by Jab1. As
mentioned in chapter 1, the most selective way to block CMA was to silence LAMP-2A
and/or Hsc70, since selective chemical inhibitors for CMA are not currently available
(144). Therefore, to confirm that Jab1 degrades PTEN through the CMA, I will
knockdown either Hs70 or LAMP-2A in breast cancer cells and compare PTEN protein
levels in the presence or absence of Jab1 over-expression.
In general, the completion of these studies will solidify the finding that Jab1
facilitates PTEN degradation through the CMA pathway in breast cancer cells.

 To identify whether PTEN is required for the resistance to trastuzumab mediated
by Jab1 over-expression
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My studies in chapter 3 and chapter 5 demonstrated that inhibition of Jab1
increased PTEN protein level and sensitized trastuzumab-resistant cells to the
treatment of this drug. As discussed in chapter 1, up-regulation of PTEN alone also
enhanced trastuzumab’s inhibitory effects on the cell proliferation. To identify whether
PTEN is required for Jab1 to mediate cells’ responses to trastuzumab, I will stably
silence Jab1 in HER2+ breast cancer cells that lack PTEN protein expression or have
non-functional PTEN. MTS assay will then be used to evaluate how these conditions
affect responses of the cells to trastuzumab treatment. If PTEN is required for Jab1 to
mediate trastuzumab resistance, trastuzumab will show no effect on the proliferation of
the PTEN-deficient cells regardless of Jab1 status.
In general, the completion of these studies will provide insights into how Jab1
modulates the resistance to trastuzumab in HER2+ breast cancer cells. Clinically
speaking, these findings will help guide the selection of patients for the treatment with
trastuzumab based on PTEN and Jab1 levels.
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